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The thesis aims to evaluate factors pertaining to reporting Adverse Drug Reactions 
(ADRs) among healthcare professionals- medical doctors and pharmacists- in Nigeria 
by conducting a questionnaire-based survey and phone interviews for quantitative 
and qualitative analysis respectively. To achieve this, the knowledge, awareness and 
challenges faced by medical professionals in relation to ADR reporting were 
considered in order to determine effective recommendations to improve ADR 
reporting practices and pharmacovigilance in Nigeria.  
 
Both groups of healthcare professionals were compared to determine their opinions 
on frequency of observed and reported ADRs, reasons for high underreporting rates, 
awareness of ADR reporting methods, guidelines and regulations as well as the 
NAFDAC regulatory body responsible for handling submitted ADR reports. A total of 
104 out of 140 responded to the survey, of whom 53 (75.7%) were medical doctors 
and 51 (72.9%) were pharmacists. Interestingly, 34.0% of medical doctors who 
responded did not know how to report ADRs compared to just 5.9% of pharmacists 
who responded. From the analysis conducted, the pharmacists had better 
knowledge, awareness and experience over medical doctors regarding ADR reporting 
in Nigeria. However, an overwhelming 90.0% of both groups of respondents opted 
for ADR reporting being made compulsory as a professional obligation towards 
pharmacovigilance. 
 
The inaccessibility of ADR report forms when needed, complex reporting procedures, 
busy work schedules and lack of time remained the most challenging factors to ADR 
reporting while fear of legal liabilities or the clinical knowledge to identify ADRs were 
among the least challenges reported. Organising pharmacovigilance conferences and 
continuous education programs to improve awareness among healthcare 
professionals and including ADR reporting courses during undergraduate 
professional training will improve knowledge of ADR reporting. Establishing ADR 
departments in healthcare institutions headed by ADR specialists and offering 
incentives in the form of professional recognition rather than financial rewards are 
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“Wherever the art of Medicine is loved, there is also a love of Humanity.”    
― Hippocrates  
The art of medicine constitutes prescribing, dispensing and administering of drugs by 
healthcare professionals (medical doctors and pharmacists) respectively. The 
effectiveness of these professionals and healthcare institutions in these areas is of 
paramount importance in fighting diseases, promoting optimal health and general 
wellbeing of patients. Through continuous innovation in research and development 
of drug substances, the pharmaceutical companies strive to ensure that the efficacy 
and safety of drug products are not compromised.  
To maintain the highest standards for new drugs, the regulatory authorities ensure 
that strict guidelines are enforced during clinical trial phases and post market 
authorisation. Clinical trials only commence after pre-clinical studies in the lab are 
typically carried out using test tubes or animals. The ideal stages for a clinical trial 
involve phase 1 which comprises of safety studies on humans, phase 2 which 
includes expanded safety studies on a larger number of humans to determine the 
efficacy of drug substance to disease and adequate dosage specifications. Then 
phase 3 is conducted to ascertain drug effectiveness in treating a condition when 
compared to available treatment options and phase 4 trials are conducted to identify 
long term effects of the new drug after it is approved and enters the market. 
 
Figure 1: Phases of Clinical Trials (MS Research Australia, 2019) 
 
Figure 2: Pharmacovigilance in Phase 4 Clinical trials. 
 
However, unfortunately after a new drug is approved, licensed and released to the 
market, the drug safety information available is usually limited. This is inevitable as 
the sample size of patient population involved during the clinical trials is small in 
comparison to the actual population of patients dependent on these prescription 
drugs. This phase marks the beginning of pharmacovigilance activities which includes 
ADR reporting. Children, young adults and elderly patients receiving concurrent drug 
therapies with pre-existing comorbidities are the most predisposed, hence there is a 
global concern to reduce the rates of adverse reactions emanating from these 
susceptible set of patients.  
Adverse event is an overview for any harm that occurs to a patient which can be 
temporarily associated with the use of a medicinal product or a therapeutic 
mechanism but may not be directly the cause of such medical occurrence. Side 
effects of drugs on the other hand are regular unintended occurrences at normal 
dose of a medicinal product as a result of the pharmacological properties of the drug 
substance and they equally negatively impact the general patient population. 
Adverse drug reaction is an example of adverse events which apart from impacting 
negatively the patients’ population, also strains the health care resources of a 
community.  
Accordingly, the World Health Organisation (WHO) defines an adverse drug reaction 
as a response to a drug that is noxious and unintended and occurs at doses normally 
used in man for prophylaxis, diagnosis or therapy of disease or for the modification 
of physiological function.’ It can either be an unexpected adverse reaction or a 
serious adverse reaction. It is unexpected when the reaction observed or reported is 
inconsistent with the applicable medicinal products’ information or drug 
characteristics. It becomes serious when such a medical occurrence at any given dose 
of such a medicinal product results in the patient being hospitalised, prolongs the 
duration of hospitalisation, causes remarkable incapacitation or disability, becomes 
life threatening or even results in death. The severity of ADRs can be grouped as 
minor, moderate, serious or lethal. 
Minor: This requires no extended hospitalisation, no therapeutic intervention or 
antidote. 
Moderate: This would usually require a change in the current drug therapy, an 
alternative treatment and may require a few days of extended hospitalisation. 
Serious/Lethal: This is usually life-threatening and will require intensive medical 
intervention. It can result in significant permanent damage or even death of the 
patient directly or indirectly. 
Most researchers classify ADRs traditionally into five types: 
1. Type A reactions- These are sometimes called augmented reactions. They are 
dose dependent and are predictable based on the pharmacology of the drug. 
They are preventable and despite their high incidence and morbidity, the rate 
of mortality associated with them is comparatively low. Common examples in 
this category include haemorrhage associated with the use of anticoagulants, 
drowsiness associated with the use of benzodiazepines, bradycardia 
associated with the use of beta blockers, etc. 
2. Type B reactions- These are also referred to as bizarre reactions which are not 
easily predictable based on the pharmacological mechanism of the drug at 
normal dosages. In contrast with the type A category, the rate of incidence 
and morbidity were relatively lower while the mortality rate associated with 
them were higher. A typical example is observed when a general anaesthesia 
is administered which can result in malignant hypothermia. 
3. Type C reactions- These are referred to as chronic reactions. They are dose 
and time related with effects due to the accumulation of a drug over a long 
time. Some typical examples are seen in osteoporosis associated with an 
extended corticosteroid treatment resulting in organ damage. 
4. Type D reactions- These are also called Delayed reactions. They are also dose 
and time related and becomes apparent sometime after the use of the drug. 
Some examples are seen in the use of tetracyclines resulting in teeth 
discolouration, carcinogenesis, patent ductus arteriosus and in the classical 
thalidomide disaster. 
5. Type E reactions- These are classified as End of Use reactions and occurs soon 
after the withdrawal of a drug. Examples are noted in rebound hypertension 
after a centrally acting antihypertensive drug has been discontinued, opioid 
withdrawal syndrome, benzodiazepines and steroids. 
 














 Organ Damage Carcinogenicity  Masking of 
diseases 
Poisoning  Immunosuppression   Exacerbation 
of disease 
Intolerance      
Table 1: Classifications of ADRs 
 
An alternative and more comprehensive form of classification is based on the Dose of 
the drug, Time course of the adverse reaction and other significant susceptibility 
factors such as genetics, pathological and other biological differences (DOTS). The 
advantage of this classification style over others is that it helps healthcare 
professionals deduce the right diagnosis and prevention of ADRs in practice. 
(Coleman and Pontefract, 2016) 
So, in order to reduce or even eradicate the impact of ADRs on the health and 
general well-being of patients, pharmacovigilance was introduced in healthcare. 
Pharmacovigilance as defined by the World Health Organisation is the science and 
activities relating to the detection, assessment, understanding and prevention of 
adverse events or any other medicine related issue. Its main goal is to encourage the 
safe and rational use of medicinal products which in turn improves general patient 
care and public health.  
Regulatory Authorities 
Several regulatory authorities serve to ensure that drugs available to the public are 
safe, efficacious and of highest attainable quality. Their scope of operation consists 
of stipulating and implementing pharmaceutical regulations related to research and 
development, drug product registration, manufacturing, distribution, pricing, 
marketing and intellectual property protection. They aim to protect patients from 
undue harm by eliciting previously undetermined drug hazards, identifying any 
predisposing factors, countering false safety signals generated either by spontaneous 
reporting, published case reports, cohort studies or post-marketing clinical trials. 
Some examples of regulatory agencies across the world include: 
 
COUNTRY REGULATORY AUTHORITY 
Nigeria National Agency for Food and Drug Administration and Control 
(NAFDAC) 
UK Medicines and Healthcare Products Regulatory Agency (MHRA) 
USA Food and Drug Administration (FDA) 
Ireland  Health Products Regulatory Authority (HPRA) 
Canada  Health Canada 
Europe European Medicines Agency (EMEA) 
Netherlands Medicines Evaluation Board 
India Central Drug Standard Control Organisation (CDSCO) 
Italy  Italian Pharmaceutical Agency 
Singapore Centre for Pharmaceutical Administration Health Sciences 
Authority 
Hong Kong Department of Health: Pharmaceutical Services 
Sweden Medical Products Agency (MPA) 
China State Food and Drug Administration 
Germany Federal Institute for Drugs and Medical Devices 
Malaysia National Pharmaceutical Control Bureau, Ministry of Health 
South Africa Medicines Control Council 
Uganda Uganda National Council for Science and Technology (UNCST) 
Japan 
Ministry of Health, Labour & Welfare (MHLW) 
INTERNATIONAL ORGANISATIONS 
World Health Organisation (WHO) 
Pan American Health Organisation (PAHO) 
International Conference on Harmonisation (ICH) 
World Intellectual Property Organisation (WIPO) 
Table 2: Regulatory Authorities and International Organisations(Sengar and Tripathy, 
2011) 
These regulatory measures became necessary after the thalidomide tragedy which 
influenced worldwide concerns for the safety of pharmaceutical drugs just as much 
as for the efficacy of the drug. Through the world health organisation program for 
international drug monitoring in 1968, studies and researches were put in place to 
advance pharmacovigilance globally. Through the program, all the member countries 
maintained a point of unified contact for gathering, analysing and sharing data 
gathered from individual incident reports worldwide. These member countries 
establish WHO-certified national pharmacovigilance centres where healthcare 
professionals can send individual case safety reports. VigiBase is the central WHO 
global database Uppsala Monitoring centre (UMC) where regionally collected reports 
are forwarded. 
Several countries are members of this global WHO program, including Nigeria who 
joined the WHO program in 2004. According to the WHO programs’ first set of 
regulations published in 2005, every hospital and tertiary healthcare institution with 
more than 50 beds for admissions is expected to employ a pharmacovigilance 
contact person, whose responsibility is to promote such pharmacovigilance activities 
including reporting ADRs, providing relevant education and training to healthcare 
professionals. Current legislation makes it the responsibility of all healthcare 
professionals to report all suspected or serious ADRs which are observed with new 
and existing medicines as well as those currently under review. This includes ADRs 
not listed in the drugs leaflet containing the summary of product characteristics, 
those due to the ineffectiveness of medicines, vaccines and drugs for treating chronic 
or life-threatening diseases, those due to misuse, abuse or overdose and those 
arising from the unregulated use of herbal products. 
There are several possible ways of creating awareness for ADRs, nevertheless 
spontaneous reporting using the yellow cards for reporting has significantly 
contributed to better standards of pharmacovigilance. The Yellow card scheme is the 
UK system for gathering and collating information on suspected or unexpected ADRs 
to medicinal products. This scheme was founded in 1964 by Bill Inman after the 
thalidomide tragedy and is managed by the Medicines and Healthcare Products 
Regulatory Agency (MHRA) and Commission on Human Medicines. Apart from its use 
to report ADRs on licensed medicines and vaccines, it can also cover reports 
emanating from herbal medications, traditional concoctions and other unlicensed 
medicines generally.  Later on, it was expanded to include hospital and community-
based pharmacists (Connelly, 2018) and offered more opportunity for people to 
report more adverse events and other suspected reactions. In 2015, a smartphone 
application to supplement the yellow card scheme was developed for both apple-iOS 
and google-android users to encourage a widespread participation, allowing patients 
and healthcare professionals to report ADRs, enabling alert updates from news 
pertaining to specific drugs and knowing how many yellow cards report a specific 
drug has received over time. (MHRA, GOV.UK, 2015) 
Previous studies suggest the critical importance of healthcare professionals as it 
pertains to spontaneous reporting of ADRs and in developing a repository of ADR 
databases. While some studies have established that the bulk of responsibility lies 
mainly with medical doctors prescribing the medications, it is yet to be established 
whether pharmacists and other cadres of healthcare professionals play equally 
critical roles in the monitoring and reporting of ADRs particularly among the general 
patient population. Despite better awareness and attitudes to ADRs recently, under 
reporting remains a major challenge of spontaneous reporting. The low rates of ADR 
reporting among the diverse patient population poses a limitation to national efforts 
geared towards the identification and estimation of the risk-benefit ratio of 
medicinal products, which helps to support regulatory responses towards actionable 
issues that arise among these vulnerable patient groups. While the attitude and 
awareness of healthcare professionals towards ADRs were subjectively positive, the 
practicality of implementing adequate ADR reporting practices still faced serious 
challenges when considered. Insufficient knowledge of guidelines and regulations 
regarding ADR reporting, confusion as to who bears the ultimate responsibility of 
ADR reporting among medical doctors and pharmacists, long work time constraints, 
ineffective ADR reporting systems, poor knowledge of ADR reporting procedures, 
fear of litigation and lack of financial incentives contribute to poor reporting rates 
globally. 
 
1.2 Research Purpose: 
This research study was undertaken with the purpose of identifying and exploring 
the challenges faced by healthcare professionals in spontaneously reporting ADRs 
with the aim of improving reporting rates, promoting drug safety practices and 
reducing the burden of ADRs in the general patient population in Nigeria. Issues 
emanating from ADRs in the general patient population are highly critical because of 
drug misinformation, misuse, advanced age related physiological, biological, 
pharmacokinetic and pharmacodynamic changes observed. When these patients 
suffer from an ADR, it is very challenging to correctly predict how severe the 
outcomes are, even when the benefits of the drug prescribed clearly outweigh the 
risks. 
To adequately tackle this reality, the author proceeded with this assessment to help 
analyse the knowledge, attitude and experience of ADR spontaneous reporting 
among medical doctors and pharmacists in line with established guidelines and 
regulations by the relevant authorities in Nigeria. Although current spontaneous 
reporting practices are less than optimal, this research dissertation on ADR reporting 
was aimed at developing effective strategies which could be optimally leveraged to 
improve the frequency and quality of reporting while driving better positive health 
outcomes for patients across Nigeria. 
 
1.3 Significance of the study: 
In contrast to spontaneous reporting of ADRs recommended in tertiary healthcare 
centres and university teaching hospitals in Nigeria, there was a major gap in current 
literature towards pharmacovigilance practices and health care approaches for the 
general patient population when comparisons were made between medical doctors 
and pharmacists involved in healthcare management. Many healthcare professionals 
especially physicians mainly reported serious and life-threatening ADRs but were 
challenged by significant delays in tracking and reviewing test results and often 
expressed dissatisfaction with the established processes used in managing the 
spontaneous reporting of ADRs. The contribution of healthcare professionals to 
pharmacovigilance and ADR reporting observed in the general patient population 
helped to establish national ADR databases.  
The National Pharmacovigilance Centre in Abuja, Nigeria is important in handling and 
processing of reports while advancing the evaluation of these ADRs to establish the 
benefit-risk ratio of such prescription or over-the-counter drugs. They promote a 
greater focus on medication monitoring, necessary to restructure and implement an 
ideal framework for ADR protocols, from the prescription process, to drug 
administration and observation of signs, symptoms and laboratory 
parameters. While a high rate of ADRs is ideally encountered in practice, the factors 
mitigating against effective reporting as depicted by the opinions and perspectives of 
healthcare professionals need to be addressed. 
 
1.4 Research Objectives: 
1. To evaluate the knowledge and awareness of ADR reporting among healthcare 
professionals in Nigeria 
2. To assess challenges among healthcare professionals in the practice of ADR 
reporting in Nigeria. 
3. To make sustainable recommendations to improve ADR reporting among 
healthcare professionals in Nigeria. 
 
Research Questions: 
1. Are healthcare professionals aware of ADR reporting in Nigeria, the reporting 
methods and systems available, the applicable guidelines and regulations and 
their responsibility towards good pharmacovigilance practices? 
2. What factors pose as challenges to ADR reporting in Nigeria, predisposing to 
ADR under-reporting and poor implementation of ADR reporting and other 
drug safety practices in Nigeria? 
3. What recommendations would help to improve ADR reporting among 
Nigerian healthcare professionals in clinical practice? 
 
1.5 Structure of the study: 
The primary research for this dissertation was structured to be carried out using a 
quantitative approach which involved the use of surveys and questionnaires and 
qualitative approach using phone interviews.  
The use of questionnaires was designed for two major groups of healthcare 
professionals- medical doctors and pharmacists. First group was for the medical 
doctors who make the drug prescriptions in a University teaching hospital or tertiary 
healthcare centre while the second group was for pharmacists who dispense the 
prescribed drugs in the community or hospital pharmacy. 
Each questionnaire was divided into five distinct sections: 
1. First section requested information on demographics including bio data, 
education and level of experience. 
2. Second section requested information on knowledge of ADR reporting and its 
systems. 
3. Third section requested information on awareness of ADRs. 
4. Fourth section requested information on factors that pose as challenges 
among healthcare professionals limiting ADR reporting. 
5. Fifth section requested information on improving ADR reporting in Nigeria.  
 
A qualitative study was also carried out by conducting phone interviews with highly 
experienced healthcare professionals to explore their experience and opinions 
regarding the practice of ADR reporting in Nigeria. The opinions obtained from these 
medical doctors and pharmacists regarding the knowledge, awareness and 
challenges associated with ADR reporting helped in complementing results obtained 
from the survey to present a balanced conclusion on the subject. 
 
Hypothesis: 
Null Hypothesis: All healthcare professionals in Nigeria have at a bare minimum, a 
basic knowledge of guidelines/regulations for spontaneous reporting of ADRs and are 
aware of their unique responsibility in reporting ADRs and promoting 
pharmacovigilance with other relevant regulatory authorities. 
 
Alternate Hypothesis: There are challenges hindering pharmacovigilance and the 
spontaneous reporting of ADRs in Nigeria due to a lack knowledge of ADR 
guidelines/regulations among healthcare professionals (medical doctors and 
pharmacists) and a lack of commitment towards their respective responsibilities 





Several organisations such as the National Agency for Food and Drug Administration 
(NAFDAC) and National Pharmacovigilance Centre (NPC) continue to provide support 
and resources to facilitate pharmacovigilance and its awareness among healthcare 
professionals in Nigeria. An understanding of the challenges faced by healthcare 
professionals (medical doctors and pharmacists) in the spontaneous reporting of 
ADRs in the general patient population will help to better understand and address 
drug safety issues, improve the safety of medicines, strengthen drug safety practices, 
reduce the burden of rising healthcare costs and promote positive health outcomes 
























“As to diseases, make a habit of two things — to help, or at least, to do no harm.”  
― Hippocrates 
Nigeria is a country located on the western coast of Africa. It consists of 36 states 
including the federal capital territory known as Abuja. According to the world 
population review as of 2019, the population is currently estimated to be over 201 
million positioning it as the seventh largest in the world. Lagos State has the largest 
population with about nine million inhabitants. The Nigerian National Bureau of 
Statistics records the life expectancy rates in the country to unfortunately be the 
lowest in West Africa. (National Bureau of Statistics, 2019) 
 
 
Figure 3: Infant Mortality and Total Fertility rates in Nigeria (Shelton, 2014) 
The World Health Organisation estimates the average life expectancy to be around 
54.5 years of age. These low values are significantly attributed to numerous health 
issues currently being faced in the country with residual effects of high mortality 
rates. It is estimated that one out of every five children born in Nigeria will die before 
they reach the age of five due to the numerous health risks and burden on health 
care in Nigeria. Nevertheless, the country has a faster population growth rate of 
2.6%, which is significantly higher than other countries of the same size as current 





Figure 4: Infant Mortality rates in Nigeria compared to other Africa countries.     
(Alemu, 2017) 
 
2.2 Adverse Events and the current state of reporting in Nigeria 
Adverse events constitute an overview for any harm that occurs to a patient which 
can be temporarily associated with the use of a medicinal product or a therapeutic 
mechanism but may not be directly the cause of such medical occurrence.  The 
Clinical Indemnity Scheme (CIS) defines a clinical incident as ‘an event arising 
because of provision of, or failure to provide clinical care that results in injury, 
disease, disability, death or prolonged hospital stay for the patient’. The Health and 
Safety Authority defines an adverse event as ‘an event or circumstance which could 
have or did lead to actual or possible personal injury, personal harm, property 
damage or loss’ (Madden, 2008). An example of an adverse event is Adverse drug 
reactions (ADRs). 
With declining healthcare standards in Nigeria and the increasing population burden 
through the years, maintaining an effective reporting of ADRs remains a challenge. 
Inadequate staffing and financial remuneration of healthcare professionals continue 
to hamper positive attempts at pharmacovigilance by the government and as a 
result, ADRs remain under reported in clinical practice. While work environment 
constraints and ineffective reporting systems continue to plague efforts geared 
towards implementing WHO standards of pharmacovigilance, healthcare 
professionals lack the necessary will power to implement established guidelines and 
regulations stipulated by the relevant authorities. However, the involvement of 
healthcare professionals is necessary to improve post marketing surveillance on new 
and existing drugs and encourage drug safety practices. The unavailability of 
advanced health services and technological support to monitor, review and report 
adverse drug events constitutes several challenges for healthcare professionals with 
responsibilities towards pharmacovigilance among the general patient population. 
Increased rates of polypharmacy, prevalence of co-morbidities and wide spread use 
of herbal concoctions compounded by age-related physiological decline, 
pharmacodynamics and pharmacokinetics changes affecting drug metabolism 
contributes to increased ADRs observed in clinical practice in Nigeria.  
According to the Department of health in 2016, 52.9% of men and 53.5% of women 
aged over 65 reported chronic illness or other health problems (Hilliard, 2017). This 
presents significant implications on healthcare demands and expenditure required 
for the monitoring and reporting of ADRs necessary to enhance an understanding of 
drug safety issues and to promote drug safety practices among healthcare 
professionals. Drugs used to treat chronic diseases, reduce pain and improve health 
outcomes and quality of life are critical in the healthcare management of patients. 
The most common classes of drugs that causes ADRs in the general patients are 
gastrointestinal drugs, cardiovascular drugs, anticancer drugs and anti-inflammatory 
drugs with the most common ADRs being neurological conditions, dermatological 
reactions and gastrointestinal disturbances such as diarrhoea and vomiting. Others 
include oedema, nausea, drowsiness, headache, fatigue and malaise. Obviously, this 
like other adverse events in the health industry significantly adds strain to the health 
care resources of any community. Presently, just about one-third of hospitalised 
patients are due to adverse reactions of the drugs while other reasons include health 
deteriorations and side effects of drugs. 
In a publication titled Pattern of medications causing adverse drug reactions and the 
predisposing risk factors among medical in-patients in clinical practice: A prospective 
study, the authors established that multiple body systems and organs were usually 
affected by ADRs. The neurological system was the most frequently affected system 
noted in 169 making about 33.3% of patients studied. It was closely followed by the 
gastrointestinal system noted in 110 (21.6%) patients, the dermatological system in 
89 (17.6%) patients, and cardiovascular system in 40 (7.8%) patients. The endocrine, 
respiratory, and renal systems were equally affected in 20 (3.9%) patients 






Figure 5: Frequency of ADR involvement and body organ/system affected. (Akhideno 
et al., 2019) 
 
2.3 Pharmacovigilance and Adverse Drug reactions reporting 
Pharmacovigilance is a practice that detects, assesses or prevents any drug related 
issue or associated adverse events to maintain the continuous monitoring of 
medicines for patients’ safety. To achieve this, ADR reports, clinical trial results and 
epidemiological studies must be regularly evaluated. Since the pharmaceutical 
industry and regulatory bodies have the patients’ well-being as their main concern, 
good pharmacovigilance and post-market surveillance practices helps to improve 
patient health outcomes and contribute towards future clinical research and drug 
development. (Talbot and Nilsson, 1998).  
A paper published in 2012 was aimed at investigating the knowledge and attitude of 
resident doctors towards ADR reporting while suggesting possible ways to improve it. 
They encouraged pharmacovigilance which helps to detect and identify ADRs and 
their associated risk factors and that the issue of under reporting can be improved by 
making healthcare professionals more knowledgeable about pharmacovigilance. 
Using a cross-sectional questionnaire-based survey, respondents who were all 
resident doctors provided information which were considered for analysis. With a 
response rate of 93.3% from a total of 84 questionnaires, 64.3% admitted to being 
aware of pharmacovigilance, 52.4% were aware of ADR reporting system in India, 
83.3% suggested that only serious ADR should be reported while 35.7% believed that 
ADRs should be reported only for newly authorised and marketed drugs. Even 
though about 67.9% of responders admitted having observed ADRs only 25.0% 
reported it. 44.0% were aware of the complete procedure involved with ADR 
reporting. The general attitude towards ADR reporting were denoted by 15.2% who 
felt it should be compulsory, 41.7% suggested it should be voluntary, 3.6% felt it 
should be remunerated, 21.4% suggested that the identity of the prescriber should 
be concealed, and 29.7% wanted the identity of the reporter concealed. From the 
results, the authors concluded that an increase in awareness of pharmacovigilance 
will help improve ADR reporting as well as having ADR reporting guidelines available 
in booklets and displayed as posters. (Pimpalkhute et al., 2012) 
Reporting of ADRs is a significant hallmark of pharmacovigilance. Over the last half of 
a century, spontaneous reporting systems such as the yellow card scheme in the UK 
has continued to be the most reliable method of detecting and reporting ADRs. This 
scheme was founded in 1964 after the thalidomide tragedy occurred in the late 
1950’s. This is operated by the Medicines and Healthcare Products Regulatory 
Agency (MHRA) and the Commission on Human Medicines (CHM). Through 
spontaneous reporting, data can be collected on suspected ADRs for both licensed 
and unlicensed medicines and vaccines either through prescriptions or those bought 
over the counter. A typical report is said to be valid when it contains four vital items 
of information: an identifiable patient, an adverse reaction, a suspected medicinal 
product, and an identifiable reporter. It is also encouraged to give additional 
information where possible to give better clinical context for regulatory assessors of 
such reports. (Coleman and Pontefract, 2016) 
Spontaneous reporting systems which have been widely utilised for 
pharmacovigilance are very effective when the adverse event is rare, uncommon 
(observed in less than 1.0% of treated cases) and event is typical of a drug-induced 
condition. They are limited when used to identify a small increase in the rate of 
common events like a stroke or myocardial infarction. The Clinical Practice Research 
Datalink (CPRD) presents an opportunity to analyse drug exposures and potential 
adverse events in such databases. They are anonymous UK primary care records 
which can help in supporting or refuting the existence of potential signals. Other 
alternative data sources utilised for pharmacovigilance includes formal drug safety 
studies, published data, pharmaceutical company data from periodic safety update 
reports and shared international data. (Coleman and Pontefract, 2016) 
 
2.4 Who is responsible for Reporting Adverse Drug Reactions? 
Healthcare professionals (medical doctors and pharmacists) are the primary 
reporters encouraged to report ADRs observed during their practice and 
involvements with patients. As noted in a survey conducted by the European 
Commission (EC), about 5.0% of hospital admissions in Europe are due to ADRs while 
5.0% of hospitalised patients experience an ADR during their time on admission.  
ADRs represent the fifth most common cause of death in the hospital setting, 
resulting in about 200,000 patient mortality in the European Union (EU) alone yearly. 
The healthcare cost burden of these ADRs in the EU was approximately €80 billion in 
2008. (Giardina et al., 2018). Since the clinical trials are usually limited in the studies 
about a medicine’s safety until it is introduced into the market and widely used by 
patients and consumers, it is imperative that the responsibility to report ADRs among 
healthcare professionals be properly determined to provide a basis for further 
research and drug investigations. (HPRA, 2019) 
In Ireland, the Health Products Regulatory Authority (HPRA) oversees the duty of 
operating the national adverse reaction reporting system and monitoring for drug 
safety. The information generated from pharmacovigilance helps in updating 
notifications on drug labelling, analysing drug-risk patterns, and encouraging 
additional investigations to prevent these adverse drug reactions. The newly 
generated data helps to foster appropriate regulatory modalities that guides drug 
researchers, healthcare professionals and pharmaceutical companies. (Council for 
International Organisations of Medical Sciences, 2000) 
Medical doctors and pharmacists are the earliest healthcare professionals to have 
contacts to the hospitalised patients and are expected to report ADRs observed from 
newly authorised or old drug products and vaccines which have been listed as 
require further monitoring. (Steinman et al., 2011). This highlights the importance of 
drug safety assessments for healthcare professionals during daily patient 
management reviews for hospitalised and out-patients. An awareness of the 
pharmacology (pharmacodynamics and pharmacokinetics) and toxic profiles of 
administered drugs is critical in observing for ADRs in order to adequately report 
them for guidance and follow up support. (HPRA, 2018) 
 
2.5 Challenges Faced Among Healthcare Professionals in Reporting Adverse Drug 
Reactions 
 
In relation to challenges in reporting ADR, the language problem is very persistent. 
Clinicians communicate verbally with one another and with their patients. When 
reporting ADRs or their suspicions, physicians will most times be reporting a clearly 
defined or well-known disease. But the challenge is that many of the terms used in 
reporting bear different meanings in different medical settings. In order not to 
corrupt the information obtained at the primary source, it is encouraged not to use 
terms different from what the patient used except there is an acceptable reason to 
do so or there is a clear, precise and well-established definition given in medicine 
textbooks. For example, in the Prescription-Event Monitoring Program, there was an 
obvious difference in the terms used by the patients and those the clinicians were 
inclined to impose when referring to a patients’ complaint of persistent dry cough. As 
a result, while framing initial reports of ADRs, the character of the clinical complaint 
and its nature can be lost. (Council for International Organisations of Medical 
Sciences, 2000) 
A research article titled Perceptions of doctors to adverse drug reactions reporting in 
a teaching hospital in Lagos, Nigeria was aimed at evaluating the knowledge and 
attitudes of doctors in a teaching hospital regarding spontaneous reporting in Lagos, 
Nigeria and to draw up suggestions geared towards improving this method of 
reporting. This study was carried out with a total of 120 medical doctors working at 
the Lagos State University Teaching Hospital (LASUTH) in Nigeria who were evaluated 
using a questionnaire to ascertain their knowledge and attitudes to ADR reporting, 
factors which they perceived may influence ADR reporting, and levels of education 
and training on ADR reporting. The study highlights factors that result in ADR under 
reporting among healthcare professionals which were broadly categorised as 
personal and professional characteristics of healthcare professionals and their 
knowledge and attitude towards reporting. They highlighted factors such as legal 
aspects involving the fear of litigation, problems associated with knowledge and 
attitude to ADRs, complacency resulting in the belief that serious ADRs have already 
been well documented by the time a drug is authorised and being circulated in the 
market, financial incentives resulting in expectation of rewards towards professional 
activities and for reporting ADRs, diffidence which tends to suggest that reporting an 
ADR is only worth doing if there was absolute certainty that it was related to the use 
of a specific drug, indifference that contributes to the belief that a single case of ADR 
an individual healthcare professional might observe could not significantly contribute 
to medical knowledge or make a difference to national drug safety practices, 
ignorance suggesting that it is only necessary to report serious, life-threatening and 
unexpected ADRs, lethargy involving procrastination and lack of enthusiasm towards 
ADR reporting or just a sheer lack of time and will power to find a report card as well 
as other applicable excuses. (Oshikoya and Awobusuyi, 2009) 
Of the factors listed from a global perspective, a review of the determinants of ADR 
under reporting associated with the healthcare professionals suggests that financial 
incentives, fear and ambition to publish contributed less significantly to under 
reporting. However, the factors resulting in the under reporting of ADRs in Africa 
have not yet been extensively studied. According to the authors, only two previous 
studies have attempted to analyse these factors in African countries, one of which 
indicates inadequate knowledge among resident doctors about ADRs, hence the aim 
of this study. The questionnaire was the method used to seek the necessary 
information. The response rate was 82.5% with most of the respondents about 
89.9% who considered doctors as the most qualified healthcare professional to 
report ADRs. 40 of the respondents making about 40.4% were aware of the National 
Pharmacovigilance Centre (NPC) in Nigeria. 32.3% of the respondents were aware of 
the Yellow card reporting scheme but only two of them had ever reported ADRs to 
the NPC. Only about half of the respondents constituting about 48.5% felt that all 
serious ADRs could be identified after the drug has been licensed, authorised and 
marketed. There was a marked difference among the number of respondents who 
believed ADR reporting should be compulsory as opposed to it being voluntary. 
(Oshikoya and Awobusuyi, 2009) 
The conclusion of the study disclosed the inadequacy of knowledge of medical 
doctors regarding ADRs and its reporting which was like reports among doctors not 
just in Nigeria but also across Europe, Asia and America. This highlighted the need for 
better undergraduate training towards pharmacovigilance and medicine risk 
perceptions as they are either insufficient or inadequately delivered to prepare 
medical doctors for their responsibilities towards ADR monitoring and reporting 
through their careers. Education and training on spontaneous reporting and the use 
of the yellow cards was highly recommended since only one of the respondents 
admitted to ever receiving such training. Although spontaneous ADR reporting 
among healthcare professionals was recommended by the NPC, it was highly 
unrecognised by the respondents. Most of them were not aware of the presence of 
the NPC while only about 39.2% of them correctly identified Abuja as the location of 
the office. Without proper knowledge of where to report ADRs, the rate of reporting 
would invariably remain poor, hence the need for heightened publicity through 
awareness programs to improve ADR reporting in Nigeria. The NAFDAC also needed 
to formulate a streamlined guideline for healthcare professionals to improve 
recognition and reporting of unusual ADRs. To improve ADR reporting over the long 
term, attitudinal and cultural changes must be imbibed which results in making ADR 
reporting an integral part of the clinical activities of the medical doctors. (Oshikoya 
and Awobusuyi, 2009) 
A study 20 years ago on the reporting of ADRs by doctors studied 118 doctors and 
determined that only about 45.0% had ever reported an ADR, with the senior doctors 
more likely to submit an ADR incident report when compared to the junior doctors. 
Worthy of note is the fact that physicians were more positively predisposed to 
reporting ADRs than the surgeons. By continuously providing reminders to report 
ADRs and by improving accessibility of yellow cards for a three-month period, 
submitted ADR report rates increased five times. This improved rate declined after 
the reminders ceased, despite the availability of yellow cards suggesting that the 
availability of the yellow cards alone does not automatically translate to improved 
ADR reporting rates among healthcare professionals. (McGettigan et al., 1997) 
ADRs leads to patient complaints and can cause non-compliance with their 
prescribed drug regimen in future. They usually mask as morbid symptoms results in 
misdiagnosis and wrong investigations and management by the healthcare 
professionals. Another recent study in Cork-based teaching hospital, published an 
incidence rate of 8.8% for ADR-related hospital admissions. (Walsh et al., 2014) 
Polypharmacy is typical among older patients as one-fifth of people aged over 50 
regularly take five or more medications daily. ADRs for drugs used to treat 
cardiovascular conditions are the most predisposed to cause ADRs. The hike in price 
for routinely prescribed Irish generic medications are massive, usually going for two 
to six times more when compared to neighbouring European countries (Richardson 
et al., 2012).  
However, the challenges emanating from the insufficient time and the inadequate 
sample size of subjects required for the clinical trial study is a huge challenge for 
pharmacovigilance. Recent pharmacovigilance practices are very dependent on post-
market surveillance and spontaneous reporting of ADRs among the healthcare 
professionals, complemented by the patient or drug user. However, persisting poor 
reporting rates of ADRs remain a hinderance to establishing adequate ADR 
databases, despite the use of electronic health records considered as secondary 
sources for data. (Lardon et al., 2015) 
As published by St James hospital in Ireland, yellow cards method for the ADR 
reporting continues to be widely recognised as an efficient surveillance system for 
ADRs observed in clinical practice. They were formalised in the 1960’s due to the 
thalidomide disaster which caused the WHO in 1968 to begin the International Drug 
Monitoring programme as a means of receiving ADR data from member countries 
contributing resources to improve evaluation of rare and serious reactions. (NMIC, 
2005) 
The value derived from the yellow card scheme is highly dependent on the 
healthcare professionals that prescribe, dispense or administer the medications. 
Despite the widespread acknowledgement of the importance of ADR reporting and 
the measures established to improve drug safety and pharmacovigilance practices 
among healthcare professionals, only few studies have explored the challenging 
factors limiting healthcare professionals towards ADR reporting. 
 
2.6 Recommendations for Improvement of Adverse Drug Reaction Reporting 
A recent study published in January 2019 on educational intervention to improve the 
knowledge, attitude and practice of healthcare professionals regarding 
pharmacovigilance in the southern parts of Nigeria was aimed at ascertaining the 
effect of a combined educational intervention. It involved delivering a seminar 
coupled with the sending of text messages monthly for a one-year duration on the 
knowledge, attitude and practice of healthcare professionals towards 
pharmacovigilance. They randomly selected six different teaching hospitals in the 
southern regions of Nigeria. This zone is made up of six states which includes Akwa-
Ibom, Bayelsa, Cross-Rivers, Delta, Edo and Rivers State. They utilised a semi-
structured questionnaire which was completed by healthcare professionals 
constituting of doctors, pharmacists and nurses working in these hospitals, from 
which appropriate data was gathered and analysed. The study was conducted from 
January 2016 to April 2017 and was designed as a repeated cross-sectional study 
with teaching hospitals which was randomised to intervention and control sites. 
(Opadeyi, Fourrier-Réglat and Isah, 2019) 
 
There were 40 questions in total concerning the nature of ADR reporting practice- 12 
questions evaluated the knowledge of the healthcare professional, 10 questions 
surrounded their attitudes and 18 focused mainly on their ADR reporting practice. 
The questionnaire contained and sought information such as age, duration of 
practice, sex, institution, knowledge of ADRs and associated definitions, reporting 
systems, and questions on the regulatory body responsible for pharmacovigilance 
and the location of the national centre for pharmacovigilance in Nigeria, perceptions 
towards pharmacovigilance, willingness to accept incentives for reporting, previous 
ADRs reported and ADR report form handling process and other associated reporting 
practices in their health institutions. (Opadeyi, Fourrier-Réglat and Isah, 2019) 
 
A total of 811 healthcare professionals with 65.0% in the intervention arm and 35.0% 
in the control arms participated in the pre-intervention study which was carried out 
in 2016. The corresponding response rate was 70.8% while 931 healthcare 
professionals in the repeated cross-sectional study corresponded in a response rate 
of 77.6% with 64.0% for the intervention arm and 36.0% for the control arm. The 
participants of both the pre intervention and post intervention surveys were similar. 
From the analysis of the post intervention questionnaire, there was a distinct 
increase in knowledge across several items between the groups. The healthcare 
professionals from the intervention group were better informed with improved 
knowledge that ADRs can result from the pharmacological attributes of the drug, can 
persist for a long time and can also occur with newly licensed and marketed 
medicines, vaccines and biological drug products. As regards knowledge of what to 
report, most of the responders in the intervention group acknowledged that they 
were more likely to submit reports of life-threatening and serious ADRs. According to 
the information gathered from the post intervention questionnaire, there was a 
remarkable increase in awareness among the intervention arm of the existing 
southern zonal pharmacovigilance centre as well as the national ADR reporting form 
when compared to the control group. Further analysis of the post intervention 
questionnaire depicts that those respondents in the control arm still preferred the 
medical doctors to file ADR reports despite the belief that all categories of healthcare 
professionals could make a report of ADRs. (Opadeyi, Fourrier-Réglat and Isah, 2019) 
 
Prior to the educational intervention, there was no significant difference in the 
attitude of reporting among both groups. In the post intervention questionnaire, 
respondents in the control group had significantly improved positive attitudes when 
compared to those from the intervention group in most of the recorded items, 
except for when they must report their suspicion of an uncertain ADR. However, the 
ideation on the relevance of reporting ADRs was not different between the groups. 
An increase of 24.0% was noted among the healthcare professionals in the 
intervention group who had received training in ADR reporting when compared to 
11.6% of those in the control group after the intervention. The proportion of 
healthcare professionals from the intervention group who had ever observed an ADR 
was markedly increased from 73.4% to 82.0%. Of the 188 who had ever reported an 
ADR, 41.0% from the intervention group admitted to using the national ADR 
reporting form compared with 19.8% from the controls. From the respondents of the 
intervention group who had ever reported an ADR using the national ADR reporting 
form, 18.6% were able to access the form when compared with 9.9% in the control 
arm. ADR reporting in the intervention group was also significantly higher and 
recorded 29.8% as against 18.7%. The authors concluded that the educational 
intervention resulted in an improvement in the knowledge and practice of 
pharmacovigilance and ADR reporting while better specific interventions would 
result in more improved attitudinal changes. A streamlined reporting process will 
further improve the practice of pharmacovigilance among healthcare professionals. 
(Opadeyi, Fourrier-Réglat and Isah, 2019) 
 
A research paper published in 2016 on the knowledge and attitude of healthcare 
professionals towards pharmacovigilance and ADR reporting in Northern Cyprus was 
carried out with 90 community pharmacists, 98 nurses and 71 medical doctors to 
investigate the knowledge, attitude and perceptions of healthcare professionals 
towards pharmacovigilance and ADR reporting. Using a face to face questionnaire 
method, only 13.0% of pharmacists, 2.0% of nurses and 20.0% of the physicians had 
knowledge about pharmacovigilance. While most of these healthcare professionals 
could not define pharmacovigilance correctly, only the pharmacists and medical 
doctors mostly (77.8% and 97.2% respectively) could define ADR correctly as 
compared to 85.7% of nurses who could not. The medical doctors received more ADR 
complaints from patients (53.5%) when compared to pharmacists (32.2%) and nurses 
(11.5%), however medical doctors reported ADRs significantly less than pharmacists 
(10.3%) and nurses (3.3%). Sadly, none of the respondents had knowledge on how to 
access the ADR reporting forms. The reasons cited for under-reporting included, time 
constraints, inadequate clinical knowledge of ADRs, where to report and how to 
report them, avoiding legal liability, ignorance on how to reach ADR forms and ADR 
reporting not being compulsory. The authors concluded that specific 
pharmacovigilance education would be the core solution to the lack of knowledge 
and attitude among healthcare professionals regarding under reporting and issues 
surrounding drug safety. There should be trainings to foster a mutual understanding 
and collaboration among healthcare professionals, leveraging on the competencies 
of each other. (Toklu et al., 2016) 
  
A 15-year review from 1983 to 1997 was conducted to evaluate reports of 
spontaneous adverse events by primary reporter composed mainly of healthcare 
professionals. They sought to explore whether a group of major primary reporter 
(healthcare professionals) categories including primary care physicians, pharmacists, 
consultants/specialist physicians, nurses and others had any impact on the quality 
and type of adverse event reports collected. A thousand spontaneous reports were 
generated randomly from the safety database across seven major categories of 
primary reporters. They also had another objective to ascertain the quality of the 
selected reports among the different reporters. But since the evaluation of the 
quality of information provided in the event report was rather subjective, an 
alternative objective method was used to evaluate the usefulness of the report by 
measuring the completeness of the data provided across the major fields such as 
demographics including age and sex of patient, dosing information including the 
dose, duration and indication as well as the general event description and 
information. (Hornbuckle, Wu and Fung, 1999) 
 
According to their report, literature seemed to suggest that pharmacists were the 
most enthusiastic category of reporters of ADRs while physicians were more likely to 
submit a more complete, thorough and possibly more accurate report of adverse 
drug events.  They cited studies that suggested that physicians-in-training (residents 
and interns) were more predisposed to having a positive attitude towards 
pharmacovigilance and drug safety reporting when compared to more senior 
physicians. Also, among the categories of healthcare professionals who were primary 
reporters, those who worked in a hospital were more likely to inquire and report an 
ADR when compared to the same categories of healthcare professionals who were 
working in a rural community setting or an out-patient establishment. (Hornbuckle, 
Wu and Fung, 1999) 
 
The worldwide safety database of the drug manufacturers was analysed for all post-
marketing adverse drug event reports which had a clearly identifiable primary 
reporter among the seven categories being studied. The spontaneous reports 
submitted directly by healthcare professionals to the drug manufacturers or 
indirectly through the regulatory authorities were referred to as post-marketing 
adverse event reports. The time duration through which the 15-year reporting period 
was from March 1, 1983 to December 31, 1997 with a total of 89,592 identified post-
marketing adverse event reports. The database covered a total of 135 different post-
marketed drugs which were manufactured by the pharmaceutical companies across 
42 therapeutic drug classes globally. (Hornbuckle, Wu and Fung, 1999) 
 
From the results obtained, consultant/specialist physicians appeared to most 
commonly report serious adverse drug events with 30.4% of the 1000 reports 
followed by primary care physicians with 20.2%. Overdose events were most 
frequently reported by pharmacists with 4.6%. Pharmacists were also more likely to 
report cases of lack of drug effect and those of more allergic reactions more than 
other categories of reporters as they were expected to report more drug interactions 
due to their educational training and direct handling of medications. 
As regards the completeness among the four data fields assessed, demographic and 
general event data appeared to be more complete among all the categories of 
healthcare professional reporters analysed than for the concomitant and dosing 
fields. Primary care physicians in general provided the highest percentage of 
completion for all the data fields in the post-marketing adverse event reports. The 
study was concluded by noting that with a positive change and improvement in the 
knowledge and attitudes of healthcare professionals towards pharmacovigilance and 
drug safety and adverse events reporting, there will invariably be an impact in the 
quantity and quality of the adverse event report collected. The authors highlighted 
the importance of promoting programs that support adverse drug event reporting in 
order to improve their usefulness in pharmacovigilance and drug safety. (Hornbuckle, 
Wu and Fung, 1999) 
  
An article published in 2014 titled Adverse Drug Event reporting: Awareness is not 
Enough, described the several post-marketing surveillance methods with the national 
voluntary reporting system being a critical component for collecting information 
concerning specific adverse events surrounding medications. In the United States, 
the Food and Drug Administration (FDA) handles a MedWatch program that collects 
voluntary reports from healthcare professionals and consumers about ADRs and 
other errors related to drugs, biologics, nutritionals and medical devices. The Vaccine 
Adverse Event Reporting System (VAERS) collect data concerning voluntary reports 
on adverse events from vaccines. This program is co-sponsored Food and Drug 
Administration and the Centre for Disease Control and Prevention (CDC). Other 
voluntary programs founded by the Institute of Safe Medication Practices: 
Medication Errors Reporting (ISMP MERP) and National Vaccine Reporting Program 
(ISMP VERP) all serve to allow individuals to confidentially report an incident for the 
analysis of data which helps to observe for potential trends, identify problems and 
provide information to optimise patient safety for the global health community. 
(Generali, 2014) 
  
But the challenge of under reporting presents a limitation which results in a variance 
of the quality of reports received. This is because most of the national reporting 
programs depends on voluntary participation. But despite these limitations, the 
MedWatch, VAERS, and ISMP programs results in a positive impact on patient care 
by encouraging better drug safety practices. Continuous participation of healthcare 
professionals continue in the voluntary reporting of adverse drug events is essential 
in promoting patient and safety. The involvement of pharmacists in patient care and 
their role in ADR reporting requires that they have knowledge and awareness of 
these programs. But recent studies that evaluated the knowledge and attitude of US 
pharmacists regarding ADR showed that despite positive attitudes towards reporting, 
most pharmacists have never reported an adverse drug event to the MedWatch 
program or admit that their knowledge regarding the reporting mechanisms and 
systems is inadequate. The United States is not the only country facing same 
discrepancy as several international studies carried out document a lack of 
pharmacist awareness and experience with ADR reporting which invariably deters 
participation in similar national programs globally. (Generali, 2014) 
  
In conclusion, the author determined that knowledge and awareness is not enough 
without the necessary experience in assessing ADRs and reporting same. She 
encouraged pharmacy schools and faculties to include ADR assessment and reporting 
experiences in their various didactic and experiential curricula. A training model can 
be used to improve familiarity with reporting mechanisms such as the newly released 
FDA’s program called MedWatch Learn which has been directed at teaching 
healthcare professionals on how to complete the online FDA forms needed to report 
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2.7 The Nigerian Approach to Pharmacovigilance 
With the significant burden of communicable and non-communicable diseases 
plaguing Nigeria, there is a consequent high use of medication. As a result, there is a 
positive initiative by the government through its Ministry of Health, regulators and 
healthcare professionals on the need for drug safety. The National 
Pharmacovigilance centre (NPC) was birthed as a result of this need, situated as an 
arm of the National Agency for Food and Drug Administration (NAFDAC) to foster 
pharmacovigilance activities in the country by serving as a repository for reported 
ADRs while also liaising with other international organisations such as the World 
Health Organisation (WHO), US Food and Drug Administration (USFDA) and the 
European Medicines Agency (EMA). Nigeria was admitted into the WHO 
International Drug Monitoring Program in 2004 with the aim of advancing drug 
safety in Nigeria, promoting a policy to define the responsibilities of stakeholders in 
pharmacovigilance, increasing public participation in drug safety measures, and 
training healthcare professionals in the country. However, the extent to which these 
objectives have been achieved remains questionable. 
The NPC has developed ADR reporting forms and guidance documents to foster 
adequate reporting of ADRs among healthcare professionals and market 
authorisation holders. In 2006, the National Drug Safety and Advisory committee 
(NDSAC) was inaugurated to review issues and provide expert perspectives on 
pharmacovigilance issues. The pharmacovigilance unit which was initially part of the 
Food and Drug Information Centre (FDIC) was eventually upgraded to a separate 
directorate in 2012 to handle post-marketing surveillance and pharmacovigilance 
issues. In 2013, zonal centres were established in the six geo-political zones in the 
country to facilitate and coordinate reporting from different parts of the country. 
The NPC receives and evaluates Individual Spontaneous Case Reports and 
disseminates information through quarterly newsletters to healthcare professionals. 
The national drug policy document issued in 1990 but revised in 2005 highlighted 
drug safety issues, providing the implementation framework that serves as a 
guidance document for the operation of the system. The NAFDAC Act Cap N1 LFN of 
2004 (amended) provides a legal backing for the activities carried out by the NPC. 
(Olowofela, Fourrier-Réglat and Isah, 2016) 
The National Agency for Food and Drug Administration and Control through the 
National Pharmacovigilance Centre has channelled efforts to improve drug safety 
practices and ADR reporting among healthcare professionals. These measures 
include providing training and tutorial seminars for healthcare professionals and 
regularly conducting public health awareness programs with discussion sessions with 
stakeholders in pharmacovigilance to review past reports of ADR and encourage the 
participation of all healthcare professionals involved in the prescription, dispensing 




Figure 6: Diagram of pharmacovigilance system of operation in Nigeria 
 
At present, reporting of ADRs is voluntary for healthcare professionals but only 
mandatory for market authorisation holders (MAH). The number of reports currently 
in the NPC database has increased to 16,222 reports between September 2004 and 
May 2015, although just about 11,000 reports have been updated to the WHO 
database. But despite the increased number of reports, Nigeria is yet to achieve the 
recommended optimal target of 200 reports per million population set by WHO. 
Inadequate recognition of ADRs, complex ADR reporting processes, lack of guidance 
materials, under-reporting, slow implementation of policies, fear of litigation or 
penalty, negative attitudes and lack of dedication to ADR reporting and 
pharmacovigilance at large, all negatively contribute to the low number of reports 
received by the NPC. Inadequate resources, infrastructural challenges, insufficient 
experts and lack of governmental support and goodwill to the pharmacovigilance 
sector made it difficult to maintain the tempo needed to surmount the challenges 
faced among these healthcare professionals in advancing ADR reporting in their 
clinical practices. (Olowofela, Fourrier-Réglat and Isah, 2016) 
  
2.8 Conclusion  
After a thorough study and corresponding review of literature on research papers 
and articles from Nigeria and all around the world, it is evident that the challenges 
surrounding ADR reporting among healthcare professionals continue to persist 
despite increased and sustained efforts towards pharmacovigilance by responsible 
regulatory authorities and health organisations to streamline reporting processes 
and educate healthcare professionals in Nigeria. The finding from the literature 
review carried out depicts an inadequate knowledge and poor attitude as the main 
factors posing challenge to improve rates of ADR reporting and quality of reports. 
Among the healthcare professionals in tertiary healthcare centres and in university 
teaching hospitals, medical doctors are traditionally seen as the leaders of the 
healthcare management team which has somewhat translated to the erroneous 
assumption that the bulk of responsibility towards reporting ADRs rests with them 
alone as they were regularly considered first among the list of primary reporters of 
ADRs. Pharmacists in comparison, although better trained to identify and report 
ADRs shy away from the responsibility as they are typically less involved in the 
management of patients in the teaching hospitals. With minimal roles revolving 
around dispensing already prescribed drugs by medical doctors from the hospital 
pharmacy, they feel less obligated to report ADRs, believing it is the responsibility of 
the physicians managing the patients. In contrast, pharmacists practicing in 
community pharmacies encounter more ADRs directly. With less stringent 
regulations regarding drug prescriptions in Nigeria, patients can easily access 
prescription as well as over the counter medications by simply walking into a 
community pharmacy, these pharmacists are better suited to encountering a 
significantly higher number of ADRs with new and existing drugs and can contribute 
more towards better spontaneous reporting of ADRs. 
Some of the challenges highlighted among healthcare professionals towards 
spontaneous reporting of ADRs through the literature review includes: ineffective 
ADR reporting systems and models, lack of available resources committed towards 
pharmacovigilance, mass exodus of healthcare professionals away from the failing 
Nigerian healthcare system, lack of healthcare professionals skilled and trained in 
reporting processes, limited or no financial incentives, inadequate working 
environments, excessively long work time constraints, limited awareness of 







CHAPTER 3: RESEARCH METHODOLOGY 
 
3.1 Overview  
Section. No Primary Data Part A Part B 
1 Approach Quantitative 
analysis 
Qualitative analysis 
2 Philosophy Positivism Interpretivism 
3 Source Questionnaire: 
Microsoft forms app 
distributed online 
Phone Interviews 
4 Structure 5 sections made up 
of 23 questions 
10 – 20 minutes of 
phone 
conversations 
5 Subjects Medical Doctors 
(53) 
Pharmacists (51) 
Medical Doctors (5) 
Pharmacists (5) 
Table 4: Research Methodology and Primary Data collection 
 
3.2 Research Approach 
To determine the challenges and factors limiting healthcare professionals from 
implementing ADR reporting and improving pharmacovigilance in Nigeria, the author 
applied a quantitative and qualitative research method by using questionnaire 
surveys and phone interviews.  
The survey was distributed electronically to both medical doctors and pharmacists 
who made up the main research cohorts and were requested to answer and fill the 
survey questions. This enabled the author gather appropriate information and 
applicable data used for statistical analysis. The questions sought to decipher the 
general perceptions towards ADR reporting and ascertain awareness about existing 
ADR reporting models and procedures. By determining the similarity or difference in 
perception among medical doctors and pharmacists, the author was able identify 
how best to approach these two major classes of healthcare professionals and 
proposed a recommendation that is sustainable over the long term.  
For the qualitative approach, phone interviews were conducted to understand the 
personal perspectives of highly experienced medical doctors and pharmacists 
towards ADR reporting in Nigeria, while getting their opinions on the current 
Nigerian pharmacovigilance system, the factors that they considered as challenges to 
implementing effective ADR reporting practices and recommendations for 
improvement which were feasible and sustainable. 
The data collected after the analysis from both groups approached was compared to 
the literature findings in order to articulate the authors’ concluding perspective on 
the study being carried out. 
 
3.3 Research Philosophy 
The philosophy underlying this research work was significantly that of positivism and 
interpretivism. It was implemented for this study with the aim of explaining 
information gathered from respondents which helped in predicting an applicable 
conclusion to the study conducted. The practical implication of this research was 
dependent on several quantifiable observations which helped in the statistical 
analysis of information gathered from respondents. The research aimed to progress 
through hypotheses and deductions as concepts being studied were easily 
measurable and required large numbers of randomly selected samples of medical 
doctors and pharmacists. 
The medical doctors and pharmacists were provided a highly structured 
questionnaire from which data was collected, analysed and interpreted objectively. 
The author was independent of the study and there was no inclination for human 
interference or personal interests within the study and only concentrated on the 
facts available. The independence assumed in this research was enforced using an 
electronic survey option in order to maintain minimal interactions with the research 
participants while the research was carried out, instead of a face to face 
questionnaire which presented the risk of bias and subjectivity, noting that the 
author is a medical doctor as well. 
The adoption of interpretivism towards information obtained from a qualitative 
approach utilising phone interviews methods resulted in primary data that was 
shaped by personal perspectives and values of the healthcare professionals. These 
were inclined to be subjective, yet honest and as a result its reliability and general 
representation tended to be undermined as well. However, it was also associated 
with a high level of validity as the greater level of depth and expression obtained 
from the highly experienced healthcare professionals while discussing ADR reporting 
in Nigeria was trustworthy through the philosophy of interpretivism which was 
required to obtain appropriate results from the study. 
 
3.4 Research Strategy 
The strategy of the research was to evaluate the awareness, knowledge and practice 
of ADR reporting among medical doctors and pharmacists, to understand the 
challenges faced by them in improving ADR reporting rates and to promote 
sustainable pharmacovigilance practices in Nigeria. As evidenced from the literature 
review conducted, it was evident that there was no research aimed at understanding 
challenges faced by these major groups of primary reporters by comparing the 
attitude, knowledge and awareness of ADR reporting among both groups of 
healthcare professionals in Nigeria. 
The medical doctors and pharmacists who received the survey questionnaire were 
initially informed of the purpose of the research project being conducted by the 
author as part of the academic requirements for the award of M. Sc in 
Pharmaceutical Business and Technology. The questionnaire was put together in an 
easy-to-answer format to address the peculiarities of the Nigerian healthcare 
professionals. It was administered to over 130 participants who were alumni 
members of a Nigerian University college of medicine and school of pharmacy, 
successfully practicing across the 4 geographical regions of the country.  
Survey questionnaire for Healthcare professionals: 
The questionnaire consisted of 23 questions structured under 5 sections to satisfy 
the purpose of the study for the Nigerian healthcare setting and its healthcare 
professionals using the Microsoft Forms application. The questionnaire was 
distributed electronically, and survey was completed in the absence of the author. 
This reinforces the philosophy of positivism to encourage the expression of opinions 
without any form of bias and hesitation. 
The first question was presented with an introductory letter which was designed to 
gain consent from respondents, permitting the use of their answers for the purpose 
of the research study. They were assured that the data generated from the survey 
was handled in line with general data protection regulation (GDPR) and that their 
response was kept strictly confidential. The question had to be answered before the 
respondent could participate further in the survey.  
 
3.5 Collection of Primary Data 
As described in the research strategy, primary data was collected solely using 
questionnaires, created for both medical doctors and pharmacists as the groups of 
healthcare professionals considered for the study. All 23 questions were structured 
to ascertain the opinions of healthcare professionals in Nigeria to successfully 
achieve the research objectives without any apparent gaps. 
Section 1 on demographics contained five questions with specified options provided 
for the respondents to choose from. The questions were to determine the category 
of healthcare professional and their level of experience and length of practice in the 
healthcare sector, the age group they fell into and which geographical zone of the 
country they currently practiced. 
Section 2 on knowledge of ADR reporting, and its systems in Nigeria consisted of five 
questions aimed at gathering information on ADRs knowledge, methods of reporting 
and criteria for submitting an ADR report and knowledge of organisation responsible 
for pharmacovigilance in Nigeria. 
Section 3 on awareness of ADR reporting in Nigeria consisted of five questions aimed 
at ascertaining the extent to which healthcare professionals understood ADRs, and 
who was responsible for its reporting. This included questions on the experience of 
reporting, mandatory or voluntary options for reporting and the frequency of 
reports, awareness of where to submit a report and the regulations and guidelines 
regarding ADR reporting in Nigeria. 
Section 4 on factors that posed as challenges relating to ADR reporting consisted of 
questions to determine the perception of healthcare professionals which limits 
adequate reporting rates in Nigeria and pharmacovigilance practice. 
Section 5: This consisted of questions that aimed to ascertain the respondents’ 
opinion on provided recommendations for healthcare professionals on how to 
improve ADR reporting and its system in Nigeria. 
 
3.6 Sources 
The survey questionnaire generated was distributed to groups of healthcare 
professionals over the internet using Microsoft forms application. The author 
gathered information from 104 participants comprised of 53 medical doctors and 51 
pharmacists. The author further utilised the Microsoft excel sheet to evaluate the 
information collated and produced pie and bar charts used to articulate and present 
the findings as well as to compare the responses between both groups of healthcare 
professionals.  
Additionally, phone interviews were performed with highly experienced medical 
doctors and pharmacists for better understanding of the knowledge, awareness, 
challenges encountered and recommendations for improvement towards ADR 
reporting in Nigeria. 
 
Selection of medical doctors: 
Author contacted his professional alumni forum of medical doctors from his alma 
mater in Nigeria where he explained the research topic which was aimed at exploring 
the challenges faced by healthcare professionals in Nigeria in relation to ADR 
reporting by determining the factors affecting their knowledge, attitudes and 
perception surrounding the issue. As a result, the medical doctors demonstrated a 
positive interest to partake in the survey questionnaire as well as an encouraging 
disposition to reach out for phone interviews which were successfully carried out as 
well. 
 
Selection of pharmacists 
Author reached out to the professional alumni forum of pharmacists from his alma 
mater in Nigeria, where he explained the relevance of the research topic and 
received positive feedback and interest to take part in the survey questionnaire and 
received recommendations for highly experienced pharmacists who were willing to 
participate in the phone interviews as well. 
 
3.7 Access and Ethical Issues 
A brief introductory explanation of the research topic was provided to all the 
healthcare professionals partaking in the survey questionnaire and interviews as they 
were all duly informed about the research project as part of an academic 
requirement by the author in fulfilment of his masters’ program.  
In structuring the questions contained in the survey, caution was taken to ensure no 
question requested any personal information of the respondent and that the 
questions posed were strictly relevant to the research study and its objectives. It was 
clearly noted to be a voluntary participation during which the participants had full 
prerogative to partake or not partake in the survey and were permitted to withdraw 
from participation at any time. 
 
3.8 Inclusion and Exclusion Criteria 
The healthcare professionals included in this study were medical doctors and 
pharmacists who were considered by the author as the main primary ADR reporters 
among healthcare professionals in Nigeria. The participants who declined to answer 
the questionnaire were by default considered as excluded from the study. Apart 
from these, no other specific inclusion or exclusion criteria was established in the 
enrolment of participants for this study and subsequent data analysis. 
An introductory letter was attached to the survey questionnaire with a required 
answer for their informed consent before proceeding. It was at the sole discretion of 
the healthcare professional to either participate or withdraw from the survey 
exercise. Of the groups of professionals who received the link to the questionnaire, 
those who were unwilling to participate were encouraged to ignore the forwarded 




For the research study, a quantitative and qualitative approach using survey 
questionnaires which consisted of 23 questions was distributed across two major 
cohorts of healthcare professionals and was underlined by a positivism philosophy 
which ensured an objective deduction from the measurable facts obtained. Phone 
interviews were carried out for qualitative approach which allowed for better 
insights and perspectives on the research study. 
The data collected was analysed and compared to the findings obtained during the 
literature review carried out in the previous chapter. The author hoped to ascertain 
the knowledge, attitudes and perceptions of medical doctors and pharmacists 
needed to evaluate the challenges faced by Nigerian healthcare professionals 
relating to ADR reporting, which was necessary to improve pharmacovigilance and 
drug safety practices in Nigeria.  



















CHAPTER 4: FINDINGS AND ANALYSIS 
 
4.1 Overview 
This chapter provides an avenue for the answers generated from the survey 
questionnaire to be analysed accordingly. The insights generated from the data 
assisted the author to determine the knowledge, awareness and challenges faced by 
these healthcare professionals and provided the basis for conclusion of the research 
study needed to improve ADR reporting in Nigeria. 
The analysis from phone interviews conducted with highly experienced medical 
doctors and pharmacists helped to establish any overlap with survey questionnaire 
results, literature review and the personal perspective of the author regarding ADR 
reporting among healthcare professionals in Nigeria. 
  
4.2 Demographic Data (Questions 1 – 6) 
4.2.1 Response rate:  
The survey was distributed to 140 healthcare professionals, consisting of 70 doctors 
and 70 pharmacists resulting in a total of 104 accepted responses, a response rate of 
74.2%.  
A total of 53 participants who responded were medical doctors with 36 of them 
being were male and 17 being female while in comparison, a total of 51 respondents 
were pharmacists, 24 of which were male and 25 being female. 
The improved response rate was attained after text message reminders were sent 
out at regular intervals through the time allotted. The author noticed that more 
responses were usually received immediately after the text message reminders were 
sent. 
 
4.2.2 Level of experience:  
Out of the acceptable 104 respondents who completed the questionnaire, 75 
respondents were predominantly young adults aged between 18 to 30 years. 26 
respondents were aged between 31 to 40, two respondents were aged between 41 
to 50 and just one respondent was 51 years or older. 
Many of the respondents- 39 medical doctors and 36 pharmacists who participated 
in the survey questionnaire had between one to five years of experience with only 
one medical doctor and one pharmacist having over 10 years of experience. 
 
*Key: N=North; S=South; E=East; W=West; M=Male; F=Female; U=Undisclosed 
Table 5: Demographics 
 
4.3 Adverse Drug Reaction (ADR) Reporting- Knowledge (Questions 7 – 11) 
The responses generated from this section were varied and remarkable. It was 
apparent from the survey that the knowledge base of the survey participants was 
encouraging and positive.  
 
Question 7:  
In the analysis of the participants knowledge on how to report ADRs in Nigeria, 
80.0% of respondents (35 medical doctors and 48 pharmacists) admitted to knowing 
how to report ADRs while 20.0% of respondents (18 medical doctors and three 
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Medical 
Doctors 
15 12 13 13 9 39 4 1 36 17 0 53 out of 70 75.7% 
Pharmacists 13 4 7 27 9 36 5 1 24 25 2 51 out of 70 72.9% 
 
Figure 7a: Knowledge among healthcare professionals about reporting ADRs in 
Nigeria 
 
It is interesting to note that among the respondents who participated in the survey, 
34.0% of medical doctors did not know how to report ADRs compared to just 5.9% of 
pharmacists – see Figure 7b. 
This confirms that while there is an above average knowledge among healthcare 
professionals in Nigeria on how to report ADRs as depicted from the survey, 
pharmacists are overwhelmingly more knowledgeable than their medical doctor 
counterparts as it pertains to ADR reporting. 
 
Figure 7b: Knowledge difference between doctors and pharmacists about reporting 
ADRs in Nigeria 
Question 8:  
As a follow-up to question 7, this was to ascertain the source of knowledge among 
healthcare professionals for reporting ADRs. While 19.0% of respondents opted not 
to answer, 31.0% of respondents (14 medical doctors and 18 pharmacist) admitted 
to getting ADR reporting knowledge from professional textbooks and journals, 27.0% 
of respondents (14 medical doctors and 14 pharmacists) participants from verbal 
communication with colleagues, followed closely by 19.0% of respondents (seven 
medical doctors and 13 pharmacists) with knowledge from newsletters received 
from regulatory authorities. Only 4.0% of respondents (two medical doctors and two 
pharmacists) attributed their source of knowledge to the internet and social media – 
see Figure 8. 
 
Figure 8: Source of knowledge for ADR reporting 
 
This shows that medical doctors and pharmacists in Nigeria utilise peer-to-peer 
verbal communication and professional journals as their main source of knowledge 
for ADR reporting. Pharmacists are more inclined to source knowledge from the 
NAFDAC newsletters than medical doctors. However, despite the upward trend of 
the internet and social media, very few healthcare professionals explore this source 
for knowledge on ADR reporting.  
 
Question 9:  
In order to determine the knowledge of which organisation is responsible for 
handling ADR reports and pharmacovigilance in Nigeria, an overwhelming majority 
75.0% of respondents identified the Nigerian Agency for Food and Drug 
Administration and Control (NAFDAC) when asked. 17.0% of respondents (11 medical 
doctors and seven pharmacists) selected the Pharmacists Council of Nigeria (PCN) 
while 3.0% of respondents (two medical doctors and one pharmacist) selected 
Medical and Dental Council of Nigeria (MDCN). 5.0% of respondents (three medical 
doctors and two pharmacists) selected the World Health Organisation as being 
responsible for pharmacovigilance and handling ADR reports in Nigeria – Figure 9. 
 
Figure 9: Organisation responsible for handling ADRs in Nigeria 
 
As confirmed by the survey result, while few medical doctors and pharmacists 
incorrectly selected the Pharmacists Council of Nigeria as the responsible body, an 
overwhelming majority of the healthcare professionals correctly recognised NAFDAC 
as the primary regulatory authority responsible for pharmacovigilance and handling 
ADR reports in Nigeria.  
 
Question 10:  
In ascertaining the ADR method that is familiar to Nigerian healthcare professionals, 
39.0% of respondents (eight medical doctors and 33 pharmacists) selected yellow 
cards/ADR forms, 11.0% of respondents (eight medical doctors and three 
pharmacists) selected the ADR e-reporting form while 25.0% of respondents (15 
medical doctors and 11 pharmacists) were familiar with both methods. However, 
25.0% of respondents (22 medical doctors and four pharmacists) were unfamiliar 
with any of the methods for reporting ADRs in Nigeria. 
 
Figure 10a: Familiar methods of reporting ADRs in Nigeria 
 
 
Figure 10b: Familiar methods of reporting ADRs in Nigeria 
 
As depicted in the charts in Figure 10b above, medical doctors were worse than 
pharmacists as regards the familiarity of ADR reporting methods. Most of the 
medical doctors who responded were unfamiliar with either the yellow cards, ADR 
forms or the ADR e-reporting form. While in contrast almost all pharmacist 
respondents were familiar with at least one method which is the Yellow card/ADR 
form. There was generally a poor familiarity of the ADR e-reporting form available on 
the NAFDAC website among both groups of healthcare professionals studied. 
Question 11:  
In asking for the most important criteria to be considered for submitting ADR report, 
10.0% of respondents (seven medical doctors and three pharmacists) selected 
unusual reactions, 2.0% of respondents (one medical doctor and two pharmacists) 
selected new drug product reactions, 7.0% of respondents (four medical doctors and 
three pharmacists) selected serious/life-threatening reactions while 81.0% of 
respondents (41 medical doctors and 43 pharmacists) admitted to all the listed 
options as being important to submit an ADR report. 
As depicted from the answers received, most of the medical doctors and pharmacists 
correctly identified serious/life-threatening reactions, unusual reactions and new 
drug product reactions as all being equally important when deciding on criteria to 
submit an ADR report. 
 
Figure 11: Most important criteria for submitting an ADR report 
4.4 Adverse Drug Reaction (ADR) Reporting- Awareness and experience (Questions 
12 – 21)  
The responses from this section varied across the questions posed to ascertain the 
awareness and experiences of ADR reporting among healthcare professionals. 
Question 12:  
In analysing which healthcare professional was perceived to be mainly responsible 
for reporting ADRs, an overwhelming majority, 63.0% of respondents (40 medical 
doctors and 26 pharmacists) admitted that any of the healthcare professionals can 
be responsible for ADR reporting. 13.0% of respondents (12 medical doctors and one 
pharmacist) selected medical doctors while 24.0% of respondents (one medical 
doctor and 24 pharmacists) selected pharmacists – see figure 12a. 
 
Figure 12a: Who is mainly responsible for reporting ADRs in Nigeria? 
 
Interestingly, while most medical doctors and pharmacist correctly identified that 
any group of healthcare professional were equally responsible for reporting ADRs in 
Nigeria. Many pharmacists when compared to medical doctors still believed the main 




Figure 12b: Who is mainly responsible for reporting ADRs in Nigeria? 
 
Question 13:  
Interestingly, an overwhelming 90.0% of respondents (47 medical doctors and 47 
pharmacists) felt ADR reporting should be compulsory in Nigeria compared to 10.0% 
of respondents (six medical doctors and four pharmacists) who suggested it 
remained voluntary – see Figure 13. 
 
Figure 13: Should ADR reporting be compulsory or voluntary 
Both groups of healthcare professionals clearly would opt for ADR reporting to be 
made compulsory like a professional obligation in Nigeria, depicting a favourable 
disposition to the importance of ADR reporting. 
Question 14:  
In order to determine observed ADRs and the frequency of such observations, 73.0% 
respondents (39 medical doctors and 37 pharmacists) admitted having observed an 
ADR within the past 12 months while 24.0% of respondents (13 medical doctors and 
12 pharmacists) had not observed any within their practice. Only 3.0% of 
respondents (one medical doctor and two pharmacists) were unsure.  
Both groups of healthcare professionals overwhelmingly admitted having observed 
ADRs in their practice within the past 12 months. 
 
Figure 14: Have you observed ADR within the past 12 months 
 
Question 15:  
As with the high number healthcare professionals with positive responses to 
observed ADRs from the previous question, 73.0% of respondents (40 medical 
doctors and 36 pharmacists) recorded that they have observed less than 25 ADRs in 
the same time period. Only 5.0% of respondents (five pharmacists) had observed 
more than 25 ADRs in the past year. Interestingly, 22.0% of respondents (13 medical 
doctors and 10 pharmacists) provided no answer to the question. 
As a follow-up from the response of the preceding question, this suggests a 
moderate frequency of observed ADRs among both groups of healthcare 
professionals practicing in Nigeria, with the pharmacists more likely to observe 
higher numbers of ADRs in their practice than the medical doctors. 
 
Figure 15: Average ADRs observed within the past 12 months 
 
Question 16:  
Interestingly, 36.0% of respondents (10 medical doctors and 28 pharmacists) 
admitted having reported an ADR within the past 12 months, especially when 
compared to the high number of healthcare professionals who had observed ADRs in 
the same time period. The majority 57.0% of respondents (40 medical doctors and 19 
pharmacists) indicated not to have reported an ADR in the past 12 months while 
7.0% of respondents (three medical doctors and four pharmacists) were unsure if 
they did – see Figure 16a. 
 
Figure 16a: Reported an ADR in the past 12 months 
 
 
Figure 16b: Reported an ADR in the past 12 months 
 
As depicted from the responses generated, most medical doctors had not reported 
any ADR within the past 12 months when compared to the pharmacists who had 
better ADR reporting in the same time frame. With the average number of ADRs 
regularly observed in practice among both groups of healthcare professionals, it is 
evident that the attitude towards reporting is poor in Nigeria. 
 
Question 17:  
In the analysis of number of ADRs reported on average within the past 12 months, 
40.0% of respondents (20 medical doctors and 22 pharmacists) admitted to have 
reported less than five ADRs within that time period, 7.0% of respondents (one 
medical doctor and six pharmacists) reported between six to 10 ADRs and just 3.0% 
of respondents (three pharmacists) reported 11 to 20 ADRs. However, an 
overwhelming 50.0% of respondents (32 medical doctors and 20 pharmacists) did 
not respond to the question. It is important to note that no participant reported 
more than 20 ADRs within the past 12 months according to this survey. 
 
Figure 17: Average ADRs reported in the past 12 months 
 
The answers received further strengthens the fact that most healthcare professionals 
who responded had submitted significantly less ADR reports within the past 12 
months when compared to the number of ADRs observed in the same time frame.  
 
Question 18:  
In the analysis of where healthcare professionals submit their ADR reports, 36.0% of 
respondents (11 medical doctors and 26 pharmacists) submitted an ADR report to 
the nearest pharmacovigilance centre, 10.0% of respondents (eight medical doctors 
and two pharmacists) submitted to their professional associations while 14.0% of 
respondents (seven medical doctors and eight pharmacists) admitted to reporting to 
the pharmaceutical company or drug manufacturer. Interestingly, the majority 
totalling 40.0% of respondents (27 medical doctors and 15 pharmacists) admitted to 
submitting to other sources. This is a critical gap in the survey which would be 
further explored during the phone interviews with experienced medical doctors and 
pharmacists for qualitative analysis of this research study.  
This demonstrates a discrepancy among both groups of healthcare professionals as 
regards their knowledge and awareness of where ADR reports are meant to be 
submitted. Pharmacists were more aware of the National Pharmacovigilance Centre 
located in their geographical zone and submitted their ADR reports to them. In 
contrast, medical doctors mostly reported to other unspecified options.  
 
Figure 18a: Who did you submit ADR reports in Nigeria 
 
Figure 18b: Who did you submit ADR reports in Nigeria 
 
Question 19:  
Unfortunately, only 27.0% of respondents (eight medical doctors and 20 
pharmacists) received an acknowledgement or feedback for an ADR report 
submitted while an overwhelming 73.0% of respondents (45 medical doctors and 31 
pharmacists) did not according to this survey. 
This depicts a poor acknowledgement and follow-up culture even among the 
regulatory authorities as it pertains to the handling of ADR reports in Nigeria. 
 
Figure 19a: ADR report acknowledgement or feedback 
 
 
Figure 19b: ADR report acknowledgement or feedback 
 
Question 20:  
In examining the awareness and familiarity with the guidelines and regulations 
governing ADR reporting in Nigeria, an overwhelming majority, 76.0% of respondents 
(46 medical doctors and 33 pharmacists) stated they were not familiar with the 
Nigerian guidelines and regulations pertaining to ADR reporting compared to only 
24.0% of respondents (seven medical doctors and 18 pharmacists) who were familiar 
with them. 
This confirms that most medical doctors and pharmacists were unfamiliar with the 
guidelines and regulations governing ADR reporting in Nigeria. Among those familiar 
with these guidelines and regulations, the pharmacists edged over the medical 
doctors with 39.0% of the pharmacist respondents being familiar with these 
regulations compared to just 15.0% of medical doctors that responded. 
 
Figure 20: Nigerian guidelines and regulations for ADR reporting 
 
Question 21:  
In analysing the attitude of healthcare professionals towards updating and improving 
their knowledge on ADR reporting systems in Nigeria which is a follow up to the 
previous question, an impressively 84.0% of respondents (48 medical doctors and 39 
pharmacists) were willing to update and improve on their knowledge about ADR 
reporting systems in Nigeria. Only 6.0% of respondents (six pharmacists) would not 
consider it. About 10.0% of respondents (five medical doctors and six pharmacists) 
remained indifferent and provided no answer. 
As confirmed by the answers recorded, both healthcare professionals were open to 
updating their knowledge about ADR reporting systems, despite the poor awareness 
of guidelines or regulations and the low reporting rates in Nigeria.  
 
Figure 21: Updating knowledge on Nigerian ADR reporting systems 
 
 
4.5 Adverse Drug Reaction (ADR) Reporting- Challenges (Question 22 i - ix) 
Question 22:  
In the analysis of challenges among healthcare professionals in reporting ADRs in 
Nigeria, several options were provided to the respondents to ascertain their opinions 
on the subject. The author hopes to gain insight into the position of Nigerian medical 
doctors and pharmacists on these factors that pose challenges which they agree or 
disagree accordingly.  
44.0% of respondents agreed that a busy work schedule and insufficient time to 
submit an ADR report was a factor, 28.4% respondents were neutral, while 27.5% 
outrightly disagreed.  
46.8% of respondents agreed that complex ADR reporting processes was a factor, 
33.9% of respondents remained neutral, while 19.3% of respondents disagreed.  
The largest percentage of respondents totalling 66.1% agreed that inaccessible 
report forms when needed was a factor, 20.2% respondents remained neutral, and 
13.8% respondents disagreed.  
34.9% of respondents agreed that fear of exposure to legal liabilities from patients or 
drug manufacturers, 23.9% of respondents remained neutral, while 41.3% of 
respondents disagreed.  
Interestingly, 25.7% of respondents agreed that concerns an ADR report might be 
wrong was a challenging factor to ADR reporting, with 33.0% of respondents 
choosing to be neutral while 41.3% of respondents disagreed. 
Regarding concerns that the process of filling and submitting an ADR report is extra 
unpaid work, 32.1% of respondents agreed it is a challenging factor, 18.3% of 
respondents remained neutral while 49.5% of respondents disagreed. 
37.6% of respondents recorded that the assumption there was no need to report an 
already established ADR was a factor that posed as a challenge. 18.3% of 
respondents remained neutral, while 44.0% of respondents disagreed. 
33.0% of respondents agreed that a healthcare professionals’ level of clinical 
knowledge making it difficult to diagnose an ADR is a contributory factor to 
challenges they faced. 26.6% of respondents remained neutral while 40.4% of 
respondents outrightly disagreed. 
28.4% of respondents attributed the challenges of ADR reporting among healthcare 
professionals to fear of disciplinary queries and negative impact of the ADR report 
towards other colleagues, 26.6% of respondents stayed neutral and 44.5% of 
respondents disagreed. 
 
Figure 22: Challenges among healthcare professionals in reporting ADRs in Nigeria 
 
 
4.6 Adverse Drug Reaction (ADR) Reporting- Recommendations (Questions 23 i – vi) 
Question 23:  
Drawing from the entire sections of the survey, this question aimed to provide 
considerations for the respondents to select from by agreeing or disagreeing. An 
overwhelming majority of respondents agreed with all the recommendations 
proposed in the survey as being effective towards the goal of improving ADR 
reporting in Nigeria.  
98.2% of respondents agreed that pharmacovigilance conferences and continuous 
education programs to improve awareness would be effective with just 1.8% of 
respondents remaining neutral.  
95.4% of respondents agreed that adverse drug reporting courses and modules 
should be included during professional training to improve knowledge with 4.6% of 
respondents remaining neutral.  
94.5% of respondents agreed that the current regulations governing ADR reporting in 
Nigeria should be reviewed, making it a professional obligation among healthcare 
professionals while 5.5% of respondents remained neutral. 
As it pertains to incorporating remunerations for every ADR case reported in order to 
encourage good pharmacovigilance practices among healthcare professionals, 74.3% 
of respondents agreed, 22.0% of respondents remained neutral while only 3.7% of 
respondents disagreed. 
95.4% of respondents agreed that increasing publicity about ADR reporting schemes 
in local healthcare journals would be an effective recommendation while 4.6% of 
respondents remained neutral. 
90.8% of respondents agreed that establishing an ADR department in their place of 
practice, headed by an ADR specialist to encourage drug safety practices in health 
institutions would effectively improve ADR reporting in Nigeria while 9.2% remained 
neutral. 
 




4.7 Qualitative Analysis: 
 
4.7.1 Phone interview with Highly experienced Medical Doctor (over 10 years) 
The author explored his alumni association group for contacts of five specialists: four 
Internal medicine consultants and one forensic pathologist and had phone interviews 
with them to explore their perceptions on ADR reporting in Nigeria and the 
challenges faced by medical doctors resulting under reporting of ADRs. They gave 
consent for the interview on the condition of an anonymous status, however they 
were all over 50 years of age and had been in medical practice for over 10 years. 
Three of them worked in government hospitals in the west while two had their 
private hospitals in the east of Nigeria. 
Three of the specialists admitted having observed an average of 20 ADRs in the past 
12 months but can recall submitting only a handful of reports in the same time 
period. The other two specialists said they did not bother to submit ADR reports 
anymore as they believed it did not make any difference to the management of the 
patients. They all agreed that they had never received feedbacks or updates on 
previously reported ADRs and that it took a long time for the regulatory authorities 
to decisively act on ADR reports in Nigeria. 
Sadly, none of them were aware of the ADR e-reporting form available on the 
NAFDAC website and only two were aware of the National pharmacovigilance centre 
operating in the geographical zone where they practised. Only two specialists 
admitted to having access to yellow cards or ADR forms in the government teaching 
hospitals where they consulted. 
When the specialists were asked about a gap observed from the survey 
questionnaire, in which many respondents who were young medical doctors with 
one to five years of experience selected other option when asked where they 
submitted ADR reports, they suggested that most young doctors would report ADRs 
to the next ranking medical doctor who supervises their practice or to the medical 
management instituted at their place of work. They explained that it is a factor of the 
medical training received as the medical profession is a profession of hierarchy and 
most young doctors are unaware of their responsibilities to directly report any 
observed ADR to the regulatory authorities as well. 
All the specialists admitted that the entire ADR reporting system needed to be 
reviewed by the regulatory authorities as the process currently in place does not 
encourage ADR reporting. They recommended ADR reporting to be made 
compulsory and incentivised to encourage young doctors to report ADRs. They 
further implied that more educational interventions such as seminars for practicing 
doctors and tutorial classes for medical students should be utilised to improve the 
culture of reporting ADRs in Nigeria. 
 
4.7.2 Phone Interview with Highly experienced Pharmacists (over 10 years) 
The author utilised his alumni association group for the contacts of five experienced 
pharmacists- three teaching hospital pharmacists and two community-based 
pharmacists and successfully scheduled phone interviews in order to ascertain their 
respective opinions on ADR reporting in Nigeria and the factors which they consider 
as challenges to effective reporting of ADRs among Nigerian pharmacists. They also 
gave their consent verbally for the interview and the use of information obtained on 
the condition of anonymity. They were all over 50 years of age and had been in 
practice for over 10 years.  
They all understood the importance of pharmacovigilance activities such as ADR 
reporting in Nigeria. They all admitted to regularly observing ADRs in their respective 
practices but had not reported any ADRs in the past 12 months because most of the 
ADRs they observed had all been well established over time and not unusual or life-
threatening. However, they were all aware of the regulatory authorities responsible 
for handling ADR reports and correctly identified the location of the National 
pharmacovigilance centre in their geographical location. It is important to note that 
the pharmacists working in hospitals were more likely to report ADRs than those 
working in community pharmacies as there was a more formal structure and process 
instituted in government-based teaching hospitals than in the community 
pharmacies. 
In addition, they explained that easy accessibility of drugs in pharmacies contributes 
to the prevalence of ADRs observed in among healthcare professionals in Nigeria. 
Patients can purchase most medications without prescriptions in any pharmacy shop 
and most pharmacists working in these shops tend to assume the role of doctors by 
offering treatment to patients for lesser cost. And as a result, pharmacists are 
generally less inclined to submit reports of ADRs observed as it implicates them 
resulting in disciplinary measures and suspension of license by their professional 
associations. 
Furthermore, they complained that regulatory authorities were ineffective in their 
responsibility of promoting the ADR reporting training programs that should 
encourage reporting among healthcare professionals. They also pointed out the 
peculiarity of the Nigerian healthcare system as being contributory to the difference 
in reporting rates when compared with their medical doctor colleagues as most 
patients at risk of ADRs or experiencing one would usually visit their medical doctors 
instead. The pharmacists are only approached for consult when the medication 
history is being reviewed by medical management team.  They also pointed out that 
most pharmacists would rather report ADRs to the respective drug manufacturer or 
pharmaceutical company rather than to the regulatory authority. Due to good 
existing relationships between pharmacists and drug company representatives, they 
are more likely to receive feedback from the companies than from the regulatory 
authorities. Another reason they explained was due to the inaccessibility of yellow 
cards or ADR forms when needed. 
They all recommended increased awareness and outreach programs to improve ADR 
reporting rates among healthcare professionals in Nigeria. They also approved that 
making ADR reporting a professional obligation of healthcare professionals would 
greatly improve the attitudes and culture towards ADR reporting. 
 
4.8 Conclusion 
As evidenced by the analysis and findings presented above, it has become apparent 
that most medical doctors and pharmacists have only an average knowledge and 
awareness of ADR reporting in Nigeria. They can correctly identify ADRs and the 
criteria to be considered for submitting a report, whether unusual, serious or new 
drug reactions. However, the practicality of effective reporting remains a challenge in 
Nigeria. Despite the poor attitudes and will-power to report ADRs routinely observed 
in their respective practices, they exhibited a willingness to improve and do better if 
proper continuous education and training is made available and the means of 
reporting becomes more accessible. 
The NAFDAC through the National Pharmacovigilance Centres have structured the 
ideal reporting models for the country as noted on their website, however they have 
performed poorly in fulfilling their responsibility of raising awareness, providing 
training and encouraging better drug safety practices and pharmacovigilance among 
healthcare professionals. Very few healthcare professionals are aware of the 
guidelines and regulations governing the ADR reporting system in Nigeria. The 
availability of the ADR e-reporting forms on the NAFDAC website is an information 
that is unknown among most health care professionals. The regulatory authorities 
rarely acknowledge or follow up on reported ADRs which results in poor reporting 
rates among medical doctors and pharmacists who are expected to be the primary 
reporters of ADRs.  
This is in consonance with the information from the qualitative analysis obtained 
from the phone interviews with both groups of highly experienced healthcare 
professionals being studied. They confirmed the discrepancy in high rates of ADRs 
observed in practice when compared to the current poor rate of ADR reporting in 
Nigeria. The few reports submitted, usually made for serious and life-threatening 
cases failed to generate prompt feedback or acknowledgements which inevitably 
results in little or no follow-up between the professionals and the regulatory bodies. 
The highly experienced pharmacists during the phone interviews criticised the ease 
with which patients could access prescription drugs over the counter as being the 
main causative factor to ADRs in Nigeria. Despite better awareness of regulations 
and guidelines among pharmacists, they are more likely to report ADRs to the drug 
manufacturers rather than the regulatory authorities. They explained the close 
working relationships between drug company representatives and pharmacists as 
main reason facilitating the observation. 
The factors posing challenges vary greatly among both groups of healthcare 
professionals as the challenges faced by medical doctors does not necessarily 
translate to the same challenge faced by pharmacists. However, according to survey 
results both groups tend to agree that ADR reporting should be made compulsory 
and a professional obligation in order to improve ADR reporting in Nigeria. Every 
recommendation provided received high rates of approval among both groups of 
healthcare professionals from the survey. The highly experienced professionals 
agreed with the recommendations proposed in the questionnaire. However, despite 
the overwhelming majority favouring the recommendations from both approaches, a 
few opposed the idea for extra remunerations for every ADR reports made as it 
tends to distract from the purpose of ADR reporting which is focused on 
pharmacovigilance to improve drug and patient safety in Nigeria.  
In the next chapter, further conclusions are made by the author as it regards to the 
research questions posed earlier. Comparisons from the literature review and 
primary research findings are presented, in addition to conclusions and reflections on 


























CHAPTER 5: CONCLUSIONS 
 
5.1 Answering the three main research questions: 
Question 1: Are healthcare professionals aware of Adverse drug reaction reporting in 
Nigeria, the reporting systems available, the applicable guidelines and regulations 
and their responsibility towards pharmacovigilance? 
From the responses obtained in the survey and acknowledged by experienced 
medical doctors and pharmacists during the phone interview, it is apparent that 
there is an above average awareness among the healthcare professionals towards 
the issue of ADR reporting and its importance in Nigeria. This awareness is chiefly the 
result of the education and training obtained as undergraduates of universities. As a 
result, healthcare professionals through verbal communications among colleagues 
continue to be aware of ADR reporting and the systems available in Nigeria. 
However, the responsibility of promoting an awareness of ADR reporting and 
pharmacovigilance by the Nigerian Agency for Food and Drug Administration and 
Control through its National Pharmacovigilance centres still presents a gap that 
needs to be filled. Despite evident attempts by the NAFDAC in providing a structured 
ADR reporting system as noted on their website, they have failed in translating these 
efforts to improved awareness of the established guidelines and regulations among 
the groups of healthcare professionals studied. Those who participated in this study 
encouraged regular pharmacovigilance awareness programs and better feedback 
measures targeted to healthcare professionals in order to bridge the gap created by 
the lack of awareness of basic reporting methods available.  
 
Question 2: What factors pose as challenges to ADR reporting in Nigeria, 
predisposing to ADR under-reporting and poor implementation of ADR reporting and 
other drug safety practices in Nigeria? 
As evidenced by the survey and phone interview carried out, both groups of 
healthcare professionals attribute ADR under reporting in Nigeria to the same factors 
plaguing other countries globally. These includes lack of adequate healthcare 
resources, poor training of staff, time and work constraints due to long work hours 
and limited staff numbers in healthcare institutions.  
Other factors border on the inaccessibility of ADR forms when needed, failure of 
regulatory authorities to provide feedback on time and the complex nature of the 
ADR reporting processes generally contribute to low reporting rates among 
healthcare professionals. 
The analysis of challenges impacting by ADR reporting in practice as observed by 
healthcare professionals ensure that the burden it bears on the healthcare system 
cannot be overlooked. 
 
Question 3: What suggestions and recommendations would help to improve adverse 
drug reaction reporting among healthcare professionals in clinical practice? 
Since there is only an average knowledge of ADR reporting among both healthcare 
professionals with the pharmacists seemingly more knowledgeable than medical 
doctors, the guidelines and regulations regarding ADR reporting should be 
adequately implemented to improve reporting rates in Nigeria. As noted from the 
quantitative and qualitative analysis, both groups of healthcare professionals 
mutually agree that the regulatory authorities should be more proactive by 
organising pharmacovigilance conferences and continuous education programs to 
improve awareness. Increased publicity on ADR reporting schemes should be 
promoted as well as improving accessibility of reporting methods to the healthcare 
professionals.  
It is encouraging that both groups agree that current regulations pertaining to ADR 
reporting should be reviewed to make it a professional obligation among healthcare 
professionals. Healthcare institutions should be encouraged to establish an ADR 
department, overseen by an ADR specialist in order to foster drug safety practices in 
these institutions. While incorporating renumerations for every ADR report 
submitted was met with most of the support, a critical few objected to the 
proposition believing it would distract from the purpose of ultimately ensuring 
patient safety to a money-making avenue considering the huge amounts of ADRs 
regularly observed in Nigeria. While this might be true, the author believes that 
incentivising ADR reporting would significantly improve reporting rates. Incentives 
should rather be in form of recognition and awards rather than financial 
reimbursements in order to foster pharmacovigilance and drug safety practices 
among other stakeholders in the healthcare sector. 
 
5.2 Comparing and contrasting results from primary and secondary research. 
The above average knowledge of ADR reporting and its finding among healthcare 
professionals in Nigeria is an encouraging finding when compared to similar studies 
from the literature review. The willingness to update knowledge on the issue 
remains remarkable as a positive attitude towards the subject. However, the lack of 
awareness of ADR reporting guidelines and regulations as well as the poor awareness 
and utilisation of the ADR e-reporting form presents significant challenges to 
effectively improve ADR reporting in Nigeria. This observation translates to 
significantly higher under-reporting rates when compared to western countries 
studied. Under-reporting of ADRs remain a global challenge but the reasons remain 
vastly varied across regions. The general factors ranging from indifference to ADR 
reporting, poor knowledge and accessibility of reporting methods, poor awareness of 
guidelines surrounding the reporting procedures are to great extent the same as 
observed from other studies in Nigeria and other countries. The attendant 
consequences of this pitfall results in high morbidity and mortality rates in Nigeria as 
noted in previous studies. (Fadare et al., 2011) 
While few studies on ADR reporting in Nigeria compare multiple groups of healthcare 
professionals, this study demonstrates that pharmacists are more predisposed to 
favourable outcomes regarding ADR reporting than their medical doctor 
counterparts. They have better knowledge of drug reactions and criteria 
necessitating a report, are more aware of the National pharmacovigilance centres 
around their place of practice and have better work time and less busy schedules to 
enable them submit ADR reports more often. The challenges predisposing medical 
doctors were widely different from the pharmacist with the exception that both 
groups of healthcare professionals agree that the inaccessibility of reporting 
methods when needed presents the most challenge to good reporting practices. 
(Oshikoya and Awobusuyi, 2009) 
Improving ADR reporting in Nigeria would greatly reduce the healthcare costs and 
mortality rates and further reduce the incidence of ADRs observed. A common 
theme through previous studies continues to encourage more awareness measures 
and further education as recommendations. The role of the regulatory agencies 
remains critical in sensitising the healthcare professionals and public towards good 
pharmacovigilance and drug safety practices. The efforts of NAFDAC in improving the 
knowledge resources and provision of e-reporting alternatives on their website is 
commendable. As suggested by both groups of healthcare professionals, a review of 
regulations to make ADR reporting compulsory as a professional obligation towards 
patient safety bears great potential. While financial incentives as noted from other 
studies remains unethical, incentives in the form of professional recognitions could 
encourage the implementation of effective ADR reporting practices in Nigeria. 
(Opadeyi, Fourrier-Réglat and Isah, 2019) 
 
5.3 Concluding thoughts 
5.3.1 Contributions and limitations of the Research 
The research was completed adequately, having generated data from survey 
questionnaires and phone interviews from One hundred and fourteen (114) 
respondents despite the relatively limited time available for the study. The data was 
analysed and provided in form of tables and charts for better interpretation and 
perception. While most research papers about ADR reporting focused on just a single 
group of healthcare professional, this research compared both medical doctors and 
pharmacists in one study. The survey questionnaire received responses from both 
groups of healthcare professionals practicing broadly across the 4 geographical zones 
in Nigeria.  
The main limitation is the relatively small number of highly experienced medical 
doctors and pharmacists interviewed over the phone. In addition, several other 
factors such as personal bias of the respondents and level of accuracy to recall 
details could impact the interpretation of results obtained. The potentially diverse 
opinions of other non-responders and of participants who failed to answer every 
question in the survey could have also affected the outcomes. 
While insights into NAFDACs regulatory role towards pharmacovigilance provided 
knowledge of ADR e-reporting forms and awareness of the ADR reporting systems 
from its website, the scope of the activities of its National pharmacovigilance centres 
regarding the handling and investigation of submitted ADR reports are yet to be 
established. The author believes that challenges impacting ADR reporting among 
healthcare professionals would differ across each of the 4 geographical zones in 
Nigeria as the level of education, awareness and economic developments vastly 
differ across these regions. 
The author assessed that the contributory factor with the most agreeing responses 
from both groups of healthcare professionals was the inaccessibility of ADR forms 
and yellow cards when needed. This was closely followed by the complex nature of 
the ADR reporting processes and the excessively demanding work schedules and 
time pressure on these healthcare professionals. Despite the above average 
knowledge and positive attitudes towards improving ADR reporting practices noted 
from the study, other factors elicited were met with more disagreeing responses 
than was expected, limiting the perception of challenges faced and leaving room for 
further research. 
 
5.3.2 Recommendations for practice 
From this research findings, knowledge and understanding of ADR reporting among 
healthcare professionals traditionally stems from undergraduate professional 
trainings, textbooks or journals and less from the applicable regulatory authority. 
Despite the availability of significant knowledge resources on their website, most 
healthcare professionals were either unaware of its existence or utilised the 
resources available such as the ADR e-reporting forms. This lack of awareness should 
be addressed by organising regular awareness programs aimed at generating interest 
in the issue of ADR reporting. 
The course content of the medical and pharmacy students should be reviewed to 
include modules and tutorials on pharmacovigilance and drug safety practices prior 
to graduation. They should specifically address reporting systems and methods 
available, organisations responsible for handling ADR reports, importance of ADR 
reporting, ADR classifications and criteria for submitting ADR reports.  
Additionally, healthcare institutions and pharmacies should establish an ADR 
department headed by ADR specialists to improve attitudes to reporting and 
implement record keeping systems for ADRs observed within its walls. These ADR 
specialists should be responsible for liaising with the National Pharmacovigilance 
centre close to the healthcare institution to ensure adequate feedback is obtained on 
individual reports submitted. 
 
5.3.3 Recommendations for future research 
Further research needs to be expanded to include nurses to improve spontaneous 
reporting of ADRs as they represent a critical group of healthcare professionals who 
are regularly in contact with patients and are usually the first-in-line to observe and 
report ADRs in hospitalised patients. Additionally, non-healthcare professionals 
(patients) should also be studied and compared to healthcare professionals as they 
can significantly increase the ADR database in Nigeria. This is particularly important 
as most ADRs occur outside healthcare institutions without the observation of 
trained healthcare professionals due to the use of traditional herbal medicines and 
indiscriminate purchase and use of prescription drugs without adequate regulatory 
oversight. 
There is still a potential scope to carry out research for ADR reporting focusing on 
each of the 36 states of the country and comparing results from these states with 
each other, to determine the unique challenges faced within each geographical zone 
in Nigeria. States having better ADR reporting practices and higher rates of submitted 
ADR reports can offer suggestions that are better suited to implementing ADR 
reporting and other good drug safety practices among healthcare professionals. 
Further study should be carried out with the regulatory authorities in the form of 
interviews and questionnaires to determine the challenges facing them in fully 
implementing the pharmacovigilance models among healthcare professionals and 
the patients in Nigeria. Other professional councils involved in healthcare such as the 
Pharmaceutical Council of Nigeria (PCN) and Medical and Dental Council of Nigeria 
(MDCN) should be studied as well as partners in the quest to advance 
pharmacovigilance and ADR reporting in Nigeria.  
The role of the internet and social media needs to be further researched as a tool to 
increase knowledge and awareness of ADR reporting in Nigeria. This research shows 
that despite the increased waves of social media advances and participation, very 
few healthcare professionals currently receive ADR information and knowledge from 
this source despite the active social media pages of the regulatory authorities. 
These recommendations would provide additional insights about ADR reporting in 
Nigeria. 
 
5.4 Final Conclusions 
In concluding this research and analysis on the knowledge, awareness and challenges 
of ADR reporting among healthcare professionals in Nigeria and after reviewing 
appropriate literature on the subject across the world, the author found the process 
very informative and helpful in filling the gaps regarding the perspectives of both 
medical doctors and pharmacists towards ADR reporting. 
As deduced from the literature review, global under-reporting rates were 
significantly due to lack of knowledge and resources needed to identify, observe, 
monitor or report potential ADRs.  However, while a lack of dedicated resources was 
also typical in Nigeria, the author concludes that the Nigerian healthcare 
professionals maintained an above average knowledge of ADRs and the criteria 
necessary for reporting them, unlike results from other countries studied. This was 
partly due to the persisting focus on knowledge acquisition rather than its 
practicality and implementation. The resulting effect is that ADR reporting rates 
continue to remain significantly lower than expected. According to the pharmacists, 
the low reporting rates persists despite the relatively high rates of observed ADRs in 
health institutions mainly due to the prominence of self-medication and ever-
increasing healthcare costs. The ease of purchase of prescription drugs over the 
counter without proper prescription notes facilitates this ADR prevalence and the 
lack of stringent regulatory oversight on the issue coupled with the belief that 
submitting ADR reports makes no difference in patient management results in failure 
and poor implementation of adequate ADRs reporting practices. Furthermore, the 
medical doctors cited the main factor limiting the practice of ADR reporting to the 
inaccessibility of yellow cards/ADR forms as at when needed. Inadequate work-time, 
very busy schedules, complex ADR reporting processes and inadequate awareness of 
the available reporting methods further limits the practice of ADR reporting in 
Nigeria. 
Most healthcare professionals opted for the regulatory authorities to review ADR 
reporting regulations to ensure it becomes a compulsory practice, seen as a 
professional obligation. This depicts the overwhelming willingness of most medical 
doctors and pharmacists to improve pharmacovigilance and drug safety practices in 
Nigeria. The author notes that while the NAFDAC have improved its website and 
provided an ADR e-reporting form online, they have performed poorly in educating 
the healthcare professionals on ADR reporting and creating adequate awareness to 
ensure these resources are utilised effectively. Adequate resources should be set 
aside to organise seminars on pharmacovigilance and continuous education 
programs on ADR reporting regularly, specifically targeted to healthcare 
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